WO1997004798A1 - H-y derived epitopes and uses therefor - Google Patents
H-y derived epitopes and uses therefor Download PDFInfo
- Publication number
- WO1997004798A1 WO1997004798A1 PCT/US1996/012351 US9612351W WO9704798A1 WO 1997004798 A1 WO1997004798 A1 WO 1997004798A1 US 9612351 W US9612351 W US 9612351W WO 9704798 A1 WO9704798 A1 WO 9704798A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- epitope
- hla
- antigen
- specific
- Prior art date
Links
- 239000000427 antigen Substances 0.000 claims abstract description 52
- 108091007433 antigens Proteins 0.000 claims abstract description 52
- 102000036639 antigens Human genes 0.000 claims abstract description 52
- 108010091938 HLA-B7 Antigen Proteins 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims description 39
- 210000000056 organ Anatomy 0.000 claims description 20
- 230000028993 immune response Effects 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 108010058607 HLA-B Antigens Proteins 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 230000001605 fetal effect Effects 0.000 claims description 2
- 102000006390 HLA-B Antigens Human genes 0.000 claims 1
- 239000012503 blood component Substances 0.000 claims 1
- 230000008774 maternal effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 108
- 101001088879 Homo sapiens Lysine-specific demethylase 5D Proteins 0.000 abstract description 32
- 102100033143 Lysine-specific demethylase 5D Human genes 0.000 abstract description 28
- 108090000623 proteins and genes Proteins 0.000 abstract description 27
- 101001088887 Homo sapiens Lysine-specific demethylase 5C Proteins 0.000 abstract description 18
- 102100033249 Lysine-specific demethylase 5C Human genes 0.000 abstract description 17
- 102000004169 proteins and genes Human genes 0.000 abstract description 16
- 238000002054 transplantation Methods 0.000 abstract description 11
- 210000001766 X chromosome Anatomy 0.000 abstract description 4
- 230000004720 fertilization Effects 0.000 abstract description 3
- 230000002759 chromosomal effect Effects 0.000 abstract description 2
- 238000003793 prenatal diagnosis Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 41
- 102000004196 processed proteins & peptides Human genes 0.000 description 41
- 235000001014 amino acid Nutrition 0.000 description 37
- 229940024606 amino acid Drugs 0.000 description 35
- 150000001413 amino acids Chemical class 0.000 description 30
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 28
- -1 HLA- B Proteins 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 20
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- 235000018102 proteins Nutrition 0.000 description 15
- 238000006467 substitution reaction Methods 0.000 description 15
- 210000001744 T-lymphocyte Anatomy 0.000 description 14
- 238000003556 assay Methods 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 210000001185 bone marrow Anatomy 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 206010052779 Transplant rejections Diseases 0.000 description 9
- 239000012491 analyte Substances 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 210000002593 Y chromosome Anatomy 0.000 description 7
- 238000001360 collision-induced dissociation Methods 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 4
- 108010075704 HLA-A Antigens Proteins 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 239000000032 diagnostic agent Substances 0.000 description 4
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- YPJUNDFVDDCYIH-UHFFFAOYSA-N perfluorobutyric acid Chemical compound OC(=O)C(F)(F)C(F)(F)C(F)(F)F YPJUNDFVDDCYIH-UHFFFAOYSA-N 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 3
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 3
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 229960003121 arginine Drugs 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000008105 immune reaction Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 229960003104 ornithine Drugs 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 102000005738 B7 Antigens Human genes 0.000 description 2
- 108010045634 B7 Antigens Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 2
- 108010052199 HLA-C Antigens Proteins 0.000 description 2
- 241000282418 Hominidae Species 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000001588 bifunctional effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 230000007515 enzymatic degradation Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 150000002463 imidates Chemical class 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- 230000003614 tolerogenic effect Effects 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 1
- XWHHYOYVRVGJJY-MRVPVSSYSA-N (2r)-2-amino-3-(4-fluorophenyl)propanoic acid Chemical compound OC(=O)[C@H](N)CC1=CC=C(F)C=C1 XWHHYOYVRVGJJY-MRVPVSSYSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- MJNZYJQWWCTUKS-REOHCLBHSA-N (2s)-2-(phosphonoamino)propanoic acid Chemical compound OC(=O)[C@H](C)NP(O)(O)=O MJNZYJQWWCTUKS-REOHCLBHSA-N 0.000 description 1
- HKUAWRVNDCVEHT-NSHDSACASA-N (2s)-2-(pyren-4-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC3=CC=CC4=CC=C1C2=C34 HKUAWRVNDCVEHT-NSHDSACASA-N 0.000 description 1
- WRQSUCJAKAMYMQ-YFKPBYRVSA-N (2s)-2-(thiophen-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC=1C=CSC=1 WRQSUCJAKAMYMQ-YFKPBYRVSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
- INSSYZYYMPOCNO-UHFFFAOYSA-N 2,3-dihydro-1h-1,2,3-benzotriazin-4-one Chemical class C1=CC=C2C(=O)NNNC2=C1 INSSYZYYMPOCNO-UHFFFAOYSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
- BHANCCMWYDZQOR-UHFFFAOYSA-N 2-(methyldisulfanyl)pyridine Chemical compound CSSC1=CC=CC=N1 BHANCCMWYDZQOR-UHFFFAOYSA-N 0.000 description 1
- FKJSFKCZZIXQIP-UHFFFAOYSA-N 2-bromo-1-(4-bromophenyl)ethanone Chemical compound BrCC(=O)C1=CC=C(Br)C=C1 FKJSFKCZZIXQIP-UHFFFAOYSA-N 0.000 description 1
- JQPFYXFVUKHERX-UHFFFAOYSA-N 2-hydroxy-2-cyclohexen-1-one Natural products OC1=CCCCC1=O JQPFYXFVUKHERX-UHFFFAOYSA-N 0.000 description 1
- VJINKBZUJYGZGP-UHFFFAOYSA-N 3-(1-aminopropylideneamino)propyl-trimethylazanium Chemical compound CCC(N)=NCCC[N+](C)(C)C VJINKBZUJYGZGP-UHFFFAOYSA-N 0.000 description 1
- BIGBDMFRWJRLGJ-UHFFFAOYSA-N 3-benzyl-1,5-didiazoniopenta-1,4-diene-2,4-diolate Chemical compound [N-]=[N+]=CC(=O)C(C(=O)C=[N+]=[N-])CC1=CC=CC=C1 BIGBDMFRWJRLGJ-UHFFFAOYSA-N 0.000 description 1
- ONZQYZKCUHFORE-UHFFFAOYSA-N 3-bromo-1,1,1-trifluoropropan-2-one Chemical compound FC(F)(F)C(=O)CBr ONZQYZKCUHFORE-UHFFFAOYSA-N 0.000 description 1
- QHSXWDVVFHXHHB-UHFFFAOYSA-N 3-nitro-2-[(3-nitropyridin-2-yl)disulfanyl]pyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1SSC1=NC=CC=C1[N+]([O-])=O QHSXWDVVFHXHHB-UHFFFAOYSA-N 0.000 description 1
- NLPWSMKACWGINL-UHFFFAOYSA-N 4-azido-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(N=[N+]=[N-])C=C1O NLPWSMKACWGINL-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- CKLDHDOIYBVUNP-KBIXCLLPSA-N Ala-Ile-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O CKLDHDOIYBVUNP-KBIXCLLPSA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 1
- JOTRDIXZHNQYGP-DCAQKATOSA-N Arg-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCN=C(N)N)N JOTRDIXZHNQYGP-DCAQKATOSA-N 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000282672 Ateles sp. Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical class OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000193764 Brevibacillus brevis Species 0.000 description 1
- 241000288943 Callitrichinae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 241000282513 Cebidae Species 0.000 description 1
- 241001272559 Cercopithecoidea Species 0.000 description 1
- 241001504544 Cercopithecus mona Species 0.000 description 1
- 206010068051 Chimerism Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- HKTRDWYCAUTRRL-YUMQZZPRSA-N Glu-His Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 HKTRDWYCAUTRRL-YUMQZZPRSA-N 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
- 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 206010056522 Hepatic infection Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000282596 Hylobatidae Species 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- VIWUBXKCYJGNCL-SRVKXCTJSA-N Leu-Asn-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 VIWUBXKCYJGNCL-SRVKXCTJSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- QCZYYEFXOBKCNQ-STQMWFEESA-N Lys-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QCZYYEFXOBKCNQ-STQMWFEESA-N 0.000 description 1
- 102100033246 Lysine-specific demethylase 5A Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102000013460 Malate Dehydrogenase Human genes 0.000 description 1
- 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
- 241000282537 Mandrillus sphinx Species 0.000 description 1
- NHXXGBXJTLRGJI-GUBZILKMSA-N Met-Pro-Ser Chemical compound [H]N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NHXXGBXJTLRGJI-GUBZILKMSA-N 0.000 description 1
- 108010059724 Micrococcal Nuclease Proteins 0.000 description 1
- 244000278455 Morus laevigata Species 0.000 description 1
- 235000013382 Morus laevigata Nutrition 0.000 description 1
- 101001025966 Mus musculus Lysine-specific demethylase 5D Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 241000158423 Nasalis larvatus Species 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 108010053210 Phycocyanin Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000288935 Platyrrhini Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 108010071010 Retinoblastoma-Binding Protein 2 Proteins 0.000 description 1
- 241000293825 Rhinosporidium Species 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000282695 Saimiri Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- QPFJSHSJFIYDJZ-GHCJXIJMSA-N Ser-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO QPFJSHSJFIYDJZ-GHCJXIJMSA-N 0.000 description 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 1
- 241001272562 Simiiformes Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241001493546 Suina Species 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- SXAGUVRFGJSFKC-ZEILLAHLSA-N Thr-His-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SXAGUVRFGJSFKC-ZEILLAHLSA-N 0.000 description 1
- COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000251221 Triakidae Species 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- BVZABQIRMYTKCF-JSGCOSHPSA-N Trp-Met Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCSC)C(O)=O)=CNC2=C1 BVZABQIRMYTKCF-JSGCOSHPSA-N 0.000 description 1
- BMGOFDMKDVVGJG-NHCYSSNCSA-N Val-Asp-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BMGOFDMKDVVGJG-NHCYSSNCSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000029244 acute graft vs. host disease Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- VIMWCINSBRXAQH-UHFFFAOYSA-M chloro-(2-hydroxy-5-nitrophenyl)mercury Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[Hg]Cl VIMWCINSBRXAQH-UHFFFAOYSA-M 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000005112 continuous flow technique Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- ZNOLGFHPUIJIMJ-UHFFFAOYSA-N fenitrothion Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C(C)=C1 ZNOLGFHPUIJIMJ-UHFFFAOYSA-N 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- BPMFZUMJYQTVII-UHFFFAOYSA-N guanidinoacetic acid Chemical compound NC(=N)NCC(O)=O BPMFZUMJYQTVII-UHFFFAOYSA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 108010038320 lysylphenylalanine Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- RMAHPRNLQIRHIJ-UHFFFAOYSA-N methyl carbamimidate Chemical compound COC(N)=N RMAHPRNLQIRHIJ-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- NEGQCMNHXHSFGU-UHFFFAOYSA-N methyl pyridine-2-carboximidate Chemical compound COC(=N)C1=CC=CC=N1 NEGQCMNHXHSFGU-UHFFFAOYSA-N 0.000 description 1
- 125000000250 methylamino group Chemical class [H]N(*)C([H])([H])[H] 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- YFZOUMNUDGGHIW-UHFFFAOYSA-M p-chloromercuribenzoic acid Chemical compound OC(=O)C1=CC=C([Hg]Cl)C=C1 YFZOUMNUDGGHIW-UHFFFAOYSA-M 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000000538 pentafluorophenyl group Chemical class FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 description 1
- HMFAQQIORZDPJG-UHFFFAOYSA-N phosphono 2-chloroacetate Chemical compound OP(O)(=O)OC(=O)CCl HMFAQQIORZDPJG-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- UJJDEOLXODWCGK-UHFFFAOYSA-N tert-butyl carbonochloridate Chemical compound CC(C)(C)OC(Cl)=O UJJDEOLXODWCGK-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- This invention relates to the field of immunology, especially as it concerns the transplantation of organs, tissues and cells. Description of the Background Art
- Histocompatibility antigens which differ from one individual to another, and which are most likely to elicit these responses, are called “histocompatibility” or “transplantation” antigens.
- Histocompatibility antigens that can induce transplant rejection include the class I and class II molecules of the major histocompatibility complex (MHC) , as well as a large number of so-called minor histocompatibility antigens (mHag) .
- MHC major histocompatibility complex
- mHag minor histocompatibility antigens
- mice the use of inbred strains has shown that mHag are encoded by almost 50 different allelically polymorphic loci scattered throughout the genome (1) .
- mHag have been shown to exist, although their overall number and complexity remains uncertain .
- the antigens of the "major” histocompatibility complex lead, if mismatched, to rapid graft rejection.
- the so-called “minor” histocompatibility or transplantation antigens also stimulate graft rejection, although at a slower pace than for the MHC antigens. These reactions can be life-threatening and therefore are not “minor” from a clinical standpoint (1) .
- H-Y was identified through the observation that within an inbred mouse strain, most of the male-to-female skin grafts were rejected, whereas transplants in other sex combinations nearly always succeeded (2) .
- a similar antigen exists in humans (3) and further studies have established that sex mismatch is a significant risk factor associated with graft rejection or the development of Graft-versus-host disease in bone marrow transplant recipients (3-6) .
- H-Y mismatch can lead to rejection of HLA-matched male organ and tissue grafts by female recipients, as well as of female bone marrow grafts by male recipients.
- H-Y antigen is ubiquitously expressed in different human tissues (4,7), and H-Y specific immune responses occur during the transplantation of organs, blood transfusion, and pregnancy (reviewed in 8) .
- H-Y antigens As with other mHag, the recognition of H-Y by T lymphocytes is MHC-restricted (3,9) , and it has been shown that some H-Y antigens are peptides derived from cellular proteins that are presented on the cell surface in association with MHC class I molecules (10) .
- the human H-Y gene has been mapped to the long arm of the Y chromosome (21) , while the mouse H-Y gene is believed to reside on "deletion interval 2" of the short arm of the murine Y chromosome (23) .
- the latter paper suggested that at least two and up to five distinct loci encode H-Y antigens.
- H-Y-specific CTLs 11P9 cell line
- H-Y-specific CTLs recognized fraction 28 from the male cell lysate, but not from the female lysate, suggesting that this fraction contained a CTL epitopic fragment of the H-Y antigen (10) .
- this fraction was not further resolved or characterized.
- the SMCX and SMCY Genes A mouse gene, smcy, was found in the course of a search of deletion interval 2 of the short arm of the Y chromosome (19) . The authors speculated as to the possibility that this gene encoded various antigens, including the H-Y antigen, the "serologically detected male antigen"
- SDMA spermatogenesis factor
- Spy spermatogenesis factor
- Applicants have identified a peptide fragment recognized by a human cytotoxic T lymphocyte (CTL) clone that is H-Y specific and restricted by the class I MHC molecule HLA-B7. It is believed that this fragment represents a CTL epitope of the H-Y antigen.
- CTL cytotoxic T lymphocyte
- Such a fragment, and various derivatives, mutants, and conjugates of the fragment are of value in predicting the likelihood of a severe graft-versus-host reaction to a transplant, as well as in preventing or ameliorating such a reaction.
- Fig. 1 Reconstitution of the H-Y epitope with HPLC fractionated peptides extracted from HLA-B7 molecules.
- HLA- B7 molecules were immunoaffinity purified from 2xl0 10 H-Y positive JY cells. Peptides were eluted from B7 molecules with 10% acetic acid, pH 2.2, filtered through a 10 kD cut-off filter and fractionated on a C18 reverse phase column. Buffer A was 0.1% heptafluorobutyric acid (HFBA) ; buffer B was 0.1% HFBA in acetonitrile.
- HFBA heptafluorobutyric acid
- Fig. 2 Determination of candidate H-Y peptide by mass spectrometry combined with 51 Cr release assay.
- HPLC fraction 14 from the separation shown in Fig. IB was chromatographed with an on-line microcapillary column effluent splitter as previously described (11,13)
- One-fifth of the effluent was deposited into 100 ⁇ l of culture media in microtiter plate wells for analysis with CTLs as in Fig. 1.
- the remaining four-fifths of the material were directed into the electrospray ionization source, and mass spectra of the peptides deposited in each well were recorded on a triple-quadrupole mass spectrometer (Finnigan-MAT, San Jose, California) .
- ( ⁇ ) H-Y epitope reconstitution activity measured as percent specific lysis
- ( ⁇ ) abundance of peptide 1171 measured as ion current at m/z 391.
- Fig. 3 CAD mass spectrum of peptide 1171 after conversion the R residue to ornithine. Material from second dimension HPLC fraction 14 shown in Fig. IB was treated with 70% hydrazine hydrate for 1 hour. The CAD mass spectrum was recorded on the (M+2H) +2 ion at m/z 566.
- Fig. 4 H-Y epitope reconstitution with synthetic peptides. Synthetic peptides were purified to homogeneity by reverse phase-HPLC on a Vydac C4 column. Purity was established on an analytical RP column and the quantity of each peptide was confirmed by comparing the area of the peak with that of a standard peptide. The identity of the peptides was confirmed by mass spectrometry. 51 Cr release was assayed at an effector to target ratio of 10 to 1 on T2-B7 cells that had been incubated with the indicated concentration of SMCY peptide SPSVDKARAEL (•) , or SMCX peptide SPAVDKAQAEL ( ⁇ ) . Fig. 5.
- the present invention facilitates the inhibition of an adverse immune reaction to an H-Y antigen. Since the H-Y antigen is male specific, such a reaction is most often encountered when a female receives a donation of a male-derived organ or tissue transplant. However, if a transplant from a female donor to a male recipient includes immunocytes, as would be the case with a bone marrow transplant, then the transplanted T cells could react adversely to the H-Y+ cells native to the recipient.
- One of the purposes of the present invention is to present an H-Y specific CTL epitope, as hereafter defined, to T cells in such a manner as to tolerize the T cells against a foreign H-Y antigen, thereby muting the immune response which would otherwise occur as a result of the transplantation.
- Such tolerization may be achieved by any means known in the art.
- One such means is to repeatedly administer to the recipient very small doses of the immunogen. If desired, the size of the doses may be increased from time to time as the patient's ability to tolerate the immunogen increases.
- Another means is to administer the immunogen by a route of administration, such as the oral route, which is less effective, immunogenically, than the intravenous route. See für, et al., Ann. Rev. Immunol., 12: 809-37 (1994) ; Friedman, et al. , Chem. Immunol. (Switz.) 58: 259-90 (1994) .
- TCR antagonist Another possibility is to administer an H-Y specific TCR antagonist .
- Certain antigen analogues have been found to be more efficient at inhibiting T cell activation by the parental antigen than are unrelated peptides. It has been speculated that the TCR antagonist: MHC molecule complex competitively blocks the T-cell receptor so that it is nonresponsive to processed H-Y antigens, yet does not interact with the receptor in such a manner as to cause T cell activation.
- a partial agonist could also be useful. These can signal T cells for lymphocyte production but are unable to elicit the signals required for proliferation, presumably because of some abnormality in their interaction with the T-cell receptor.
- Yet another means of inducing tolerance is to block one or more of the pathways involved in the adverse immune response.
- one may blockade the B7-CD28 or B7-CTLA4 pathway using anti-CD28 or anti-CTLA4 antibodies, and/or B7 analogues which act as antagonists by blocking the CD28 or CTLA4 binding site. See Boussiotis, et al. , Curr. Opin. Immunol. 6: 797-807 (1994) .
- the H-Y specific epitope may be presented on an incomplete antigen-presenting cell, such as a T cell genetically engineered so as not to express CTLA4, or a fibroblast cell genetically engineered to express the necessary MHC molecule but not other molecules necessary for effective antigen presentation.
- an incomplete antigen-presenting cell such as a T cell genetically engineered so as not to express CTLA4, or a fibroblast cell genetically engineered to express the necessary MHC molecule but not other molecules necessary for effective antigen presentation.
- two or more means of tolerization may be used in combination, either simultaneously or sequentially, in order to achieve a greater degree of tolerance, or to achieve tolerance more rapidly, or to achieve it with fewer side effects.
- the elements of the combination may be such that, if used alone, they would be ineffective.
- the methods of the present invention may, mutatis mutandis, be adapted to the inhibition of serum sickness attributable to a transfusion between individuals of different sexes .
- the methods of the present invention may also be helpful in damping the immune response of the mother to the fetal H-Y antigen.
- compositions of the present invention also have diagnostic value. For example, they can be used to assess the degree of chimerization of the bone marrow of a patient who has received a sex-mismatched bone marrow transplant; the post- transplant marrow may include both H-Y+ and H-Y- T cells.
- organs which may be transplanted are very long and is primarily limited by known surgical techniques. Certain tissues or parts of organs, as well as cells which are not organized into organs or tissues, also may be transplanted.
- organ includes whole organs, parts of organs, and miscellaneous tissues. Examples include kidney, eye, heart, heart valve, skin, liver, bone marrow, intestine, blood vessels, joints or parts thereof, pancreas or portions containing the islets, lungs, bronchi, brain tissue, muscle and any other vascularized tissue.
- the transfusion of blood or components thereof is not be construed as being an organ transplantation.
- Transplantation may be performed to correct an organ which is missing, incomplete, or improperly functioning as a result of injury, genetic defect, disease, toxic reaction, etc.
- the recipient may receive the transplanted organ to supplement existing tissue such as using skin tissue to treat burns, pancreatic islets for diabetes or brain tissue for Parkinson's disease.
- the recipients defective organ may be completely removed and replaced with the graft such as in kidney, heart, liver, lung or joint transplants.
- either approach may be used, such as with liver transplants for treating cirrhosis and hepatic neoplasms and infections.
- the H-Y-specific CTL epitopes of the present invention are peptides, typically 9-13 amino acids in length, which are sufficiently similar to an H-Y epitope recognized by an H-Y specific CTL to be useful, under suitable conditions of use, as tolerogens to protect an individual from an H-Y specific allogeneic response, or to be useful in the diagnosis of the susceptibility of an indiviual to such a response.
- such epitopes are identical to or otherwise substantially homologous with H-Y-specific peptide epitopes recognized by H-Y- specific CTLs. Applicants believe that SMCY is likely to be either an H-Y antigen, or at least substantially homologous with an H-Y antigen.
- these peptides may be identical to, or otherwise substantially homologous with, SMCY (which appears to be one of the human H-Y antigens) and especially to the identified SPSVDKARAEL epitope. Since, in turn, SMCX is substantially homologous with SMCY, they may also be identical or otherwise substantially homologous to SMCX (especially to its SPAVDKAQAEL sequence) .
- H-Y cell line used as a source of H-Y-specific CTL epitopes may be any H-Y cell line; similarly, the Class I MHC (HLA) molecule may be any such molecule which is capable of binding to and presenting a H-Y- specific epitope, including, but not limited to, the various allelic forms of Class I MHC molecules.
- the principal genetic loci are denoted as HLA-A, HLA- B, and HLA-C.
- the H-Y specific epitope of the present invention may be HLA-A, HLA-B or HLA-C restricted.
- the preferred epitopic sequence may vary depending on the restriction system.
- the H-Y specific epitope is one restricted by one of the more prevalent (at least among the intended patient population) allelic forms of these loci.
- HLA-A the principle alleles are HLA-A2, -A3, -Al, -All and - A24.
- HLA-B the most prevalent alleles are HLA-B7 and - B8; however, HLA-B is more polymorphic than HLA-A. Epitopes presentable by HLA-B7 are of particular interest.
- the peptide concentration at which the epitope- stimulated CTLs achieve half the maximal increase in lysis relative to background is no more than about 1 nM, more preferably no more than about 100 pM, still more preferably no more than about 10 pM.
- the potency was 10 pm. Even when a peptide is being used as a tolerogen, high potency is advantageous as it permits use of low concentrations of the peptide, which, besides being more economical, also reduces the chance of a side effect.
- the epitope is recognized by CTLs from at least two different individuals, more preferably at least five different individuals.
- the CTL epitope satisfies two or more of the above desiderata.
- the H-Y epitope of the present invention has the sequence Ser-Pro-Ser-Val-Asp-Lys-Ala-Arg-Ala- Glu-Leu (SPSVDKARAEL) , or a functional fragment thereof.
- H-Y epitopes may be identified by systematic study of the immunological properties of 9-13 amino acid fragments of SMCY. Since, until the present discovery, the connection of SMCY to H-4 was highly speculative, and SMCY had no known biological function, the art lacked the motivation to make such a study. Alternatively, other H-Y epitopes may be identified as was SPSVDKARAEL, but by screening with other H-Y specific CTLs, especially those restricted by MHCs other than HLA-B7.
- This peptide although recognized by HLA-B7-restricted H-Y- specific CTL, may not be optimal at present. It is known that some residues on CTL epitopes are particularly important for binding of the peptide to the MHC molecule, while others are particularly important for Tc recognition. The other residues may be important for either or both. (refs: E.L. Huczko et al. J. Immunol. 151:2572, 1993; J. Ruppert et al . Cell 754: 929, 1993; Madden Dr et al . Cell 75:693-708, 1994.) It is proposed that amino acid substitutions for the peptide may be useful at altering the immune response to the peptide.
- the present invention embraces epitopes which are substantially homologous with such epitopes, and therefore H-Y-specific in their own right.
- substantially homologous when used in connection with amino acid sequences, refers to sequences which are substantially identical to or similar in sequence with each other, giving rise to a homology in conformation and thus to retention, to a useful degree, of one or more biological (including immunological) activities. The term is not intended to imply a common evolution of the sequences.
- a cell line such as HLA-B7+, H-Y- T2-B7 cells
- H-Y-specific CTL epitopes e.g., HLA-B7 H-Y-specific CTLs.
- residues to vary may also make comparisons of the sequences of the naturally processed MHC associated peptides, and may obtain 3D structures of the MHC: peptide: TCR complexes, in order to identify residues involved in MHC or TCR binding. Such residues may either be left alone, or judiciously mutated in an attempt to alter MHC or TCR binding.
- T2-B7 cells for recognition had only 1/10, 000th the potency of the lead peptide.
- the purpose of the invention is not to achieve a strong immune response, but rather a muted one that serves to tolerize against the H-Y antigen, such a mutant may well be useful, indeed, it could be more useful than the native epitope.
- Ser->Ala mutation is a relatively conservative one (one small, aliphatic, uncharged a.a. for another)
- the Arg->Gln mutation is not. Further mutagenesis experiments are necessary to determine whether the change in potency is attributable to the loss of H-bonding potential (by replacing Ser with Ala) , the loss of the charge of the Arg, and/or a steric effect .
- a possible multiple mutagenesis strategy could be the following: Parental Ser Pro Ser Val Asp Lys Ala Arg Ala Glu Leu
- each amino acid sequence in the parental sequence may either be retained, or replaced by one of the amino acids in the column below it, selected independently.
- substitutions are not limited to the genetically encoded, or even the naturally occurring amino acids.
- the d- -ired amino acid may be used directly.
- a geneti .i-ly en- ed amino acid may be modified by reacting it with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues.
- an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues.
- Aromatic amino acids may be replaced with D- or L-naphylalanine, D- or L-Phenylglycine, D- or L-2-thieney- lalanine, D- or L-1-, 2-, 3- or 4-pyreneylalanine, D- or L-3-thieneylalanine, D- or L- (2-pyridinyl) -alanine, D- or L- (3-pyridinyl) -alanine, D- or L- (2-pyrazinyl) -alanine, D- or L- (4-isopropyl) -phenylglycine, D- (trifluoromethyi) - phenyl ⁇ glycine, D- (trifluoromethyi) -phenylalanine, D-p-fluoro- phenylalanine, D- or L-p-biphenylphenylalanine, D- or L-p-methoxybiphenylphenylalanine,
- Acidic amino acids can be substituted with non-carboxylate amino acids while maintaining a negative charge, and derivatives or analogs thereof, such as the non-limiting examples of
- substitutions may include unnatural hyroxylated amino acids made by combining "alkyl” (as defined and exemplified herein) with any natural amino acid.
- Basic amino acids may be substituted with alkyl groups at any position of the naturally occurring amino acids lysine, arginine, ornithine, citrulline, or (guanidino) -acetic acid, or other (guanidino) alkyl-acetic acids, where "alkyl" is define as above.
- Nitrile derivatives e.g., containing the CN-moiety in place of COOH
- methionine sulfoxide may be substituted for methionine.
- Such derivatives are expected to have the property of increased stability to degradation by enzymes, and therefore possess advantages for the formulation of compounds which may have increased in vivo half lives, as administered by oral, intravenous, intramuscular, intraperitoneal, topical, rectal, intraocular, or other routes.
- any amino acid can be replaced by the same amino acid but of the opposite chirality.
- any amino acid naturally occurring in the L-configuration (which may also be referred to as the R or S configuration, depending upon the structure of the chemical entity) may be replaced with an amino acid of the same chemical structural type, but of the opposite chirality, generally referred to as the D- amino acid but which can additionally be referred to as the R- or the S-, depending upon its composition and chemical configuration.
- Such derivatives have the property of greatly increased stability to degradation by enzymes, and therefore are advantageous in the formulation of compounds which may have longer in vivo half lives, when administered by oral, intravenous, intramuscular, intraperitoneal, topical, rectal, intraocular, or other routes.
- Additional amino acid modifications of amino acids may include the following: Cysteinyl residues may be reacted with alpha-haloacetates (and corresponding amines) , such as 2-chloroacetic acid or chloroacetamide, to give carboxymethyl or carboxyamidomethy1 derivatives.
- Cysteinyl residues may also be derivatized by reaction with compounds such as bromotrifluoroacetone, alpha-bromo- beta- (5-imidozoyl)propionic acid, chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide, methyl 2-pyridyl disulfide, p-chloromercuribenzoate, 2-chloromercuri-4-nitrophenol, or chloro-7-nitrobenzo-2-oxa-l, 3-diazole.
- compounds such as bromotrifluoroacetone, alpha-bromo- beta- (5-imidozoyl)propionic acid, chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide, methyl 2-pyridyl disulfide, p-chloromercuribenzoate, 2-chloromercuri-4-nitrophenol, or chloro-7-nitro
- Histidyl residues may be derivatized by reaction with compounds such as diethylprocarbonate e.g., at pH 5.5-7.0 because this agent is relatively specific for the histidyl side chain, and para-bromophenacyl bromide may also be used; e.g., where the reaction is preferably performed in 0.1 M sodium cacodylate at pH 6.0. Lysinyl and amino terminal residues may be reacted with compounds such as succinic or other carboxylic acid anhydrides. Derivatization with these agents is expected to have the effect of reversing the charge of the lysinyl residues.
- compounds such as diethylprocarbonate e.g., at pH 5.5-7.0 because this agent is relatively specific for the histidyl side chain, and para-bromophenacyl bromide may also be used; e.g., where the reaction is preferably performed in 0.1 M sodium cacodylate at pH 6.0.
- Suitable reagents for derivatizing alpha-amino-containing residues include compounds such as imidoesters/e.g. , as methyl picolinimidate ; pyridoxal phosphate; pyridoxal; chloroborohydride ; trinitrobenzenesulfonic acid; O-methylisourea; 2,4 pentanedione; and transaminase-catalyzed reaction with glyoxylate.
- Arginyl residues may be modified by reaction with one or several conventional reagents, among them phenylglyoxal, 2, 3-butanedione, 1, 2-cyclohexanedione, and ninhydrin according to known method steps. Derivatization of arginine residues requires that the reaction be performed in alkaline conditions because of the high pKa of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group.
- tyrosyl residues per se The specific modification of tyrosyl residues per se is well-known, such as for introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane.
- N-acetylimidizol and tetranitromethane may be used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively.
- Carboxyl side groups may be selec ⁇ tively modified by reaction with carbodiimides (R' -N-C-N-R' ) such as l-cyclohexyl-3- (2-morpholinyl- (4-ethyl) carbodiimide or 1- ethyl-3- (4-azonia-4,4- dimethylpentyl) carbodiimide.
- carbodiimides R' -N-C-N-R'
- aspartyl and glutamyl residues may be converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.
- Glutaminyl and asparaginyl residues may be readily deamidated to the corresponding glutamyl and aspartyl residues. Alternatively, these residues may be deamidated under mildly acidic conditions. Either form of these residues falls within the scope of the present invention.
- Derivatization with bifunctional agents is useful for cross-linking the peptide to a water-insoluble support matrix or to other macromolecular carriers, according to known method steps.
- Commonly used cross-linking agents include, e.g., 1, 1-bis (diazoacetyl ) -2 -phenylethane , glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'- dithiobis (suc- cinimidylpropionate) , and bifunctional maleimides such as bis-N-maleimido-1, 8-octane.
- Derivatizing agents such as methyl -3 - [ (p-azidophenyl ) dithio] propioimidate yield photoactivatable intermediates that are capable of forming crosslinks in the presence of light.
- reactive water-insoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates described in U.S. Patent Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440 (which are herein incorporated entirely by reference) , may be employed for protein immobilization.
- Derivatized moieties may improve the solubility, absorption, biological half life, and the like, or eliminate or attenuate any possible undesirable side effect of the molecule. Moieties capable of mediating such effects are disclosed, for example, in Remington's Pharmaceutical Sciences. 16th ed. , Mack Publishing Co., Easton, PA (1980) .
- Modifications are not limited to the side chains of the amino acids.
- the H-Y-specific tolerogen of the present invention is a molecule corresponding to or otherwise comprising a H-Y-specific CTL epitope as previously described.
- the tolerogen may comprise one or more H-Y-specific CTL epitopes, which may be the same or different. If different, the epitopes may be chosen so that at least one epitope is effective in each of two or more restriction systems, e.g., HLA-B7 and HLA-A2. If the tolerogen comprises a plurality of such epitopes, they may be linked directly, or through a spacer of some kind, or by noncovalent means such as an avidin:biotin complex.
- the tolerogen may take any form that is capable of eliciting a H-Y-specific tolerizing immune response.
- the tolerogenic conjugate may also comprise moieties intended to diminish the immune response, such as certain cytokines.
- H-Y non- (H-Y) specific tolerogens
- H-Y specific tolerogens may either be conjugated to the H-Y specific epitope to form a unitary tolerogen, and/or used as independent molecules (either in the same composition or in a separately administered composition administered as part of the medication schedule) .
- the peptide portion of the tolerogens of the present invention may be produced by any conventional technique, including
- the peptides disclosed herein may be produced, recombinantly, in a suitable host, such as bacteria from the genera Bacillus, Escherichia, Salmonella, Erwinia, and yeasts from the genera Hansenula, Kluyveromyces, Pichia, Rhinosporidium, Saccharomyces, and Schizosaccharomyces, insect cells, or cultured mammalian cells such as COS-l, CHO and C127.
- the more preferred hosts are microorganisms of the species Pichia pastoris, Bacillus subtilis , Bacillus brevis, Saccharomyces cerevisiae, Escherichia coli and Yarrowia lipolytica . Any promoter, regulatable or constitutive, which is functional in the host may be used to control gene expression.
- Chemical Peptide Synthesis is a rapidly evolving area in the art, and methods of solid phase peptide synthesis are well-described in the following references, hereby entirely incorporated by reference:
- such methods involve blocking or protecting reactive functional groups, such as free amino, carboxyl and thio groups. After polypeptide bond formation, the protective groups are removed (or de-protect-ed) .
- the addition of each amino acid residue requires several reaction steps for protecting and deprotecting.
- tBoc method the amino group of the amino acid being added to the resin-bound C-terminal amino acid is blocked with tert-butyloxycarbonyl chloride (tBoc) .
- This protected amino acid is reacted with the bound amino acid in the presence of the condensing agent dicyclohexylcarbodiimide, allowing its carboxyl group to form a polypeptide bond the free amino group of the bound amino acid.
- the amino-blocking group is then removed by acidification with trifluoroacetic acid (TFA) ; it subsequently decomposes into gaseous carbon dioxide and isobutylene. These steps are repeated cyclically for each additional amino acid residue.
- TFA trifluoroacetic acid
- HF hydrogen fluoride
- trifluoro-methanesulfonyl derivatives A more vigorous treatment with hydrogen fluoride (HF) or trifluoro-methanesulfonyl derivatives is common at the end of the synthesis to cleave the benzyl-derived side chain protecting groups and the polypeptide-resin bond.
- the preferred "Fmoc” technique has been introduced as an alternative synthetic approach, offering milder reaction conditions, simpler activation procedures and compatibility with continuous flow techniques.
- This method was used, e.g., to prepare the peptide sequences disclosed in the present application.
- the x-amino group is protected by the base labile 9-fluorenylmethoxycarbonyl (Fmoc) group.
- the benzyl side chain protecting groups are replaced by the more acid labile t-butyl derivatives.
- Repetitive acid treatments are replaced by deprotection with mild base solutions, e.g., 20% piperidine in dimethyl-formamide (DMF) , and the final HF cleavage treatment is eliminated.
- a TFA solution is used instead to cleave side chain protecting groups and the peptide resin linkage simultaneously.
- At least three different peptide-resin linkage agents can be used: substituted benzyl alcohol derivatives that can be cleaved with 95% TFA to produce a peptide acid, methanolic ammonia to produce a peptide amide, or 1% TFA to produce a protected peptide which can then be used in fragment condensation procedures, as described by Atherton, E., et al. , J. Chem. Soc. Perkin Trans. 1:538-546 (1981) and Sheppard, R.C., et al., Int. J. Polypeptide Prot. Res.
- compositions of the present invention may be used to protect mammals against allogeneic immune responses to a foreign H-Y antigen.
- One or more such compositions will be used as part of a tolerogenically effective medication schedule to achieve such protection.
- mammal an individual belonging to the class Mammalia, which, of course, includes humans.
- the invention is particularly useful in the treatment of human subjects, although it is intended for veterinary uses as well.
- the subject preferably belonds to the order
- Primata humans, apes, and monkeys
- Artiodactyla e.g., cows, pigs, sheeps, goats, horses
- Rodenta e.g., rabbits, mice, rats
- Carnivora e.g., cats, dogs
- Primates are especially preferred.
- non-human primate any member of the suborder Anthropoidea except for the family Hominidae.
- non-human primates include the superfamily Ceboidea, family Cebidae (the New World monkeys including the capuchins, howlers, spider monkeys and squirrel monkeys) and family Callithricidae
- the rhesus monkey is one member of the macaques.
- protection is intended to include “prevention,” “suppression” and “treatment.”
- Prevention involves administration of the protective composition prior to the induction of the disease.
- Secondary involves administration of the composition prior to the clinical appearance of the disease.
- Treatment involves administration of the protective composition after the appearance of the disease.
- the protection provided need not be absolute, provided that it is sufficient to carry clinical value.
- An agent which provides protection to a lesser degree than do competitive agents may still be of value if the other agents are ineffective for a particular individual, if it can be used in combination with other agents to enhance the overall level of protection, or if it is safer than competitive agents.
- administration may be systemic or topical.
- administration of such a composition may be by various parenteral routes such as subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intranasal, transdermal, or buccal routes.
- parenteral administration can be by bolus injection or by gradual perfusion over time.
- a typical regimen comprises administration of an effective amount of the tolerogen, administered over a period ranging from a single dose, to dosing over a period of hours, days, weeks, months, or years.
- the doses may be equal in size, or different. If different, they may increase, or decrease, in a regular manner, or otherwise.
- the physician will usually exercise medical discretion and decrease or increase the dose after consideration of the effect of the initial dose(s) on the patient.
- the interval between doses may be constant, or it may be increased or decreased.
- the suitable dosage of a tolerogen of the present invention will be dependent upon the age, sex, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired.
- the most preferred dosage can be tailored to the individual subject, as is understood and determinable by one of skill in the art, without undue experimentation. This will typically involve adjustment of a standard dose, e.g., reduction of the dose if the patient has a low body weight .
- a drug Prior to use in humans, a drug will first be evaluated for safety and efficacy in laboratory animals. In human clinical studies, one would begin with a dose expected to be safe in humans, based on the preclinical data for the drug in question, and on customary doses for analogous drugs (if any) . If this dose is effective, the dosage may be decreased, to determine the minimum effective dose, if desired. If this dose is ineffective, it will be cautiously increased, with the patients monitored for signs of side effects. See, e.g., Berkow, et al . , eds., The Merck Manual, 15th edition, Merck and Co., Rahway, N.J., 1987; Goodman, et al.
- the total dose required for each treatment may be administered by multiple doses or in a single dose.
- the tolerogen may be administered alone or in conjunction with other therapeutics directed to the disease or directed to other symptoms thereof.
- the appropriate dosage form will depend on the disease, the tolerogen, and the mode of administration; possibilities include tablets, capsules, lozenges, dental pastes, suppositories, inhalants, solutions, ointments and parenteral depots. See, e.g., Berker, supra, Goodman, supra, Avery, supra and Ebadi, supra. which are entirely incorporated herein by reference, including all references cited therein.
- compositions will include .001- 1,000 micrograms, more typically .1-1000 ⁇ g, of the peptide epitope, but applicants are not to be considered to be bound to this range. It is noted that in WO90/08162, the therapeutically effective concentration was expected to be on the order of 100 micromoles of the "replacing peptide".
- a pharmaceutical composition may contain suitable pharmaceutically acceptable carriers, such as excipients, carriers and/or auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. See, e.g., Berker, supra, Goodman, supra, Avery, supra and Ebadi, supra, which are entirely incorporated herein by reference.
- composition of the present invention may also include any compound used in the prevention or treatment of graft rejection or graft-versus-host disease, such as an immunosuppressive agent, or a less specific tolerizing agent.
- An H-Y specific diagnostic agent is (1) a molecule which is or which comprises an H-Y specific epitope as previously defined, and which is labeled, immobilized, or otherwise rendered suitable for diagnostic use, or (2) an antibody which specifically binds such an H-Y specific epitope, and which is labled, immobilized, or otherwise rendered suitable for diagnostic use.
- the diagnostic agents of the present invention may be used to screen a sample for the presence of an antigen with the same epitope, or with a different but cross-reactive epitope, or for the presence of CTLs which specifically recognize the corresponding epitopes.
- the assay may be used to determine (1) whether an intended recipient is likely to suffer, in the absence of treatment, a severe graft rejection or graft-vs . -host disease as a result of the immune response to a particular H-Y CTL epitope; and (2) whether, after transplantation of bone marrow from a female donor to a male recipient, the post-transplant hematopoietic compartment of the bone marrow include a significant number of H-Y+ (i.e., native) cells.
- H-Y+ i.e., native
- the sample will normally be a biological fluid, such as blood, urine, lymphatic fluid, amniotic fluid, semen, saliva, tears, milk, or cerebrospinal fluid, or a fraction or derivative thereof, or a biological tissue, in the form of, e.g., a tissue section or homogenate.
- the preferred sample is blood, or a fraction or derivative thereof.
- Assays may be divided into two basic types, hetero-geneous and homogeneous. In heterogeneous assays, the interaction between the affinity molecule and the analyte does not affect the label, hence, to determine the amount or presence of analyte, bound label must be separated from free label. In homogeneous assays, the interaction does affect the activity of the label, and therefore analyte levels can be deduced without the need for a separation step.
- Assays may also be divided into competitive and non- competitive formats.
- the competitive format the analyte competes with a labeled analyte analogue for binding to a binding partner.
- a sandwich assay the analyte is first bound by a capture reagent, and then by a tag reagent.
- the assay In order to detect the presence, or measure the amount, of an analyte, the assay must provide for a signal producing system
- SPS in which there is a detectable difference in the signal produced, depending on whether the analyte is present or absent
- the detectable signal may be one which is visually detectable, or one detectable only with instruments. Possible signals include production of colored or luminescent products, alteration of the characteristics (including amplitude or polarization) of absorption or emission of radiation by an assay component or product, and precipitation or agglutination of a component or product.
- the term "signal" is intended to include the discontinuance of an existing signal, or a change in the rate of change of an observable parameter, rather than a change in its absolute value. The signal may be monitored manually or automatically.
- the component of the signal producing system which is most intimately associated with the diagnostic reagent is called the
- label may be, e.g., a radioisotope, a fluorophore, an enzyme, a co-enzyme, an enzyme substrate, an electron-dense compound, an agglutinable particle.
- the radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography.
- Isotopes which are particularly useful for the purpose of the present invention are 3 H, 125 1, 131 I, 35 S, 14 C, and, preferably, 12S I .
- fluorescent labelling compounds fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o- phthaldehyde and fluorescamine.
- fluorescence-emitting metals such as 125 Eu, or others of the lanthanide series, may be attached to the binding protein using such metal chelating groups as diethyl- enetriaminepentaacetic acid (DTPA) and ethylenediamine- tetraacetic acid (EDTA) .
- DTPA diethyl- enetriaminepentaacetic acid
- EDTA ethylenediamine- tetraacetic acid
- the diagnostic agents also can be detectably labeled by coupling to a chemiluminescent compound.
- the presence of the chem-iluminescently labeled antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction.
- particularly useful chemiluminescent labeling compounds are luminol, isolumino, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.
- Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bio-luminescent compounds for purposes of labeling are luciferin, luciferase and aequorin .
- Enzyme labels such as horseradish peroxidase, alkaline phosphatase, malate dehydrogenase, staphylococcal nuclease, ⁇ -V- steroid isomerase, yeast alcohol dehydrogenase, ⁇ -glycero phosphate dehydrogenase, triose phosphate isomerase, asparaginase, glucose oxidase, -galactosidase, ribonuclease, glucose-6-phosphate dehydrogenase, glucoamylase and acetyl ⁇ choline esterase, are preferred.
- the signal producing system must also include a substrate for the enzyme. If the enzymatic reaction product is not itself detectable, the SPS will include one or more additional reactants so that a detectable product appears.
- a label may be conjugated, directly or indirectly (e.g., through a labeled antibody) , covalently (e.g., with SPDP) or noncovalently, to the epitope, to produce a diagnostic reagent.
- the epitope may be conjugated to a solid phase support to form a solid phase ("capture") diagnostic reagent.
- Suitable supports include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses, and magnetite.
- the nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention.
- the support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to its target.
- the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod.
- the surface may be flat such as a sheet, test strip, etc.
- the peptides of the present invention may be used to generate cytotoxic lymphocytes (CTL) or monoclonal antibodies (mAb) that could be used to select for male and female sperm cells, allowing for the selection of the sex of a resulting embryo after fertilization.
- CTL cytotoxic lymphocytes
- mAb monoclonal antibodies
- We and others have developed CTL that recognize peptides presented by human class I MHC molecules using mice that express the human class I molecules in transgenic form. This is accomplished by immunization of the mice with the peptide, and removal and culture of T cells from the mice in the presence of additional peptide and interleukin 2.
- Stable long term T cell lines and clones can be obtained from the spleen cell culture and used as reagents.
- these animals may be used to isolate antibodies directed against the complex of the peptide with an MHC molecule.
- Antibodies with this type of specificity have been previously reported in the literature.
- CTL or mAb could be used in either of two methods for selecting sperm of the appropriate sex.
- CTL would be added to a population of sperm.
- the CTL would directly kill any sperm cells expressing the peptide-MHC complex for which the CTL was specific.
- CTL directed against a male specific H-Y peptide and/or SMCY peptide would kill all male (Y-chromosome bearing) sperm, leaving the female (non-Y-chromosome bearing) sperm.
- a similar end could be achieved using a complement fixing mAb directed against the same antigen, after addition of complement.
- an antibody of the appropriate specificity would be coupled to a plastic dish or a magnetic bead, allowing the binding and separation of sperm bearing the appropriate antigen.
- the sperm selected would be used for fertilization of eggs, followed by reimplantation of the eggs into a suitable host.
- Cytotoxicity Assays Cell-mediated killing was determined in vitro using a 4-h chromium release assay. 51Cr-labeled target cells were plated at 2 x 10 3 cells/well in triplicate on 96-well V-bottom plates (Costar, Cambridge, MA) with varying numbers of effector cells in a final volume of 250 microl . Wells containing either culture medium and target cells only or 1 M HCl and target cells served as background 51Cr release controls and total release controls, respectively. The plates were centrifuged at 100 x g for 3 min and incubated at 37°C in 5% C02 for 4 h. The plates were again centrifuged, and 0.20 ml of medium from each well was removed for counting in a gamma counter. The cytotoxic index was calculated as: Cpm (experimental) - cpm (background)
- a lytic unit was defined as the number of effector cells needed to mediate 30% lysis of target cells. The number of lytic units was calculated per 10 5 effector cells (LU30 per 10 s cells) .
- HLA-B7 molecules were purified by affinity chromatography from the H-Y positive, B lymphoblastoid cell line, JY (14) .
- the associated peptides were extracted in acid and separated from high molecular weight material by ultrafiltration as previously described (15) , and subsequently fractionated by reverse-phase high-performance liquid chromatography (HPLC) (11) .
- each active fraction separately to a microcapillary HPLC column and split the effluent following the separation (11) : Four-fifths of the effluent was directed into the mass spectrometer for analysis, while one-fifth was simultaneously directed into a 96-well microtiter plate for a subsequent epitope reconstitution assay. The amount of the H-Y sensitizing activity in each well was correlated to signals observed in the mass spectrum, and therefore to the abundance of different peptide species. By comparing the profile of H-Y activity and the ion abundance data (Fig.
- a synthetic peptide corresponding to the 11 residue SMCY sequence was found to sensitize T2-B7 cells for recognition by the H-Y specific CTL clone.
- Half-maximal lysis was achieved at a peptide concentration of 10 pM (Fig. 4) .
- the corresponding peptide derived from the sequence of the X chromosomal homolog, SMCX has substitutions of A for S at position 3 and Q for R at position 8. Although this peptide also was able to sensitize T2-B7 cells for recognition, comparable levels of killing were only achieved by using a 10, 000-fold higher peptide concentration.
- the peptide epitope representing the HLA-B7 restricted H-Y antigen is derived from the protein encoded by SMCY.
- the H-Y antigen is a not previously identified homologoue of SMCY which happens to have the aforementioned peptide sequence in common with SMCY.
- One interesting issue is whether the H-Y epitope peptides presented by other MHC molecules will also be derived from SMCY.
- SMCY and SMCX are 85% identical at the amino acid sequence level, and the SMCX gene is expressed ubiquitously from both the active and the inactive X chromosomes in both mice and human (18,22) .
Abstract
We show that one human H-Y antigen presented by HLA-B7 is an 11 residue peptide derived from SMCY, an evolutionarily conserved Y chromosomal protein. A homologous gene on the X chromosome, SMCX, differs by two residues in the same region. The identification of H-Y offers prospects for improvements in transplantation outcome, prenatal diagnosis and fertilization strategies.
Description
H-Y DERIVED EPITOPES AND USES THEREFOR
Mention of Government Grant
Certa work performed in connection with the invention disclosed ..-rein was supported by U.S. Public Health Service Grants AI20963 and AI3993. Consequently, the U.S. Government may have certain rights in the invention.
BACKGROUND OF THE INVENTION
Field of the Invention
This invention relates to the field of immunology, especially as it concerns the transplantation of organs, tissues and cells. Description of the Background Art
In 1989, a major human organ was transplanted into another human being every 40 minutes. The 16,000 organs transplanted that year included almost 9,000 kidneys, nearly 2,000 each of hearts and livers, and close to 3,000 bone marrow transplants. Such transplants, which are from an animal of one species to another animal of the same species, are termed allografts.
A significant practical limitation on the practice of allograft therapy is the acute shortage of donor organs of all types. This shortage is exacerbated by the need to match donors and recipients for immunocompatibility. Immunological differences between donor and recipient, even though of the same species, can lead to immune rejection of a transplant (graft) . In addition, where a graft contains immunocompetent cells, these can recognize "host" antigens as foreign, leading to an adverse immune reaction known as graft-vs. -host disease.
The antigens which differ from one individual to another, and which are most likely to elicit these responses, are called "histocompatibility" or "transplantation" antigens. Histocompatibility antigens that can induce transplant rejection include the class I and class II molecules of the major histocompatibility complex (MHC) , as well as a large number of so-called minor histocompatibility antigens (mHag) . In mice, the use of inbred strains has shown that mHag are encoded by almost 50 different allelically polymorphic loci scattered throughout the genome (1) . In humans, mHag have been shown to exist, although their overall number and complexity remains
uncertain .
The antigens of the "major" histocompatibility complex lead, if mismatched, to rapid graft rejection. The so-called "minor" histocompatibility or transplantation antigens also stimulate graft rejection, although at a slower pace than for the MHC antigens. These reactions can be life-threatening and therefore are not "minor" from a clinical standpoint (1) . Even when donors and recipients are perfectly matched as determined by HLA serotyping and by mixed leukocyte culture tests, moderate to severe acute graft-vs.-host disease occurs in 30-70% of bone marrow transplant recipients and is the primary or contributing cause of death in 15-40% (6) .
Attempts have been made to control graft rejection and graft-versus-host disease by administering general immunosuppressants and, in the case of bone marrow transplants, in vitro depletion of donor marrow of T cells pretransplant. However, these strategies have the disadvantage that the immune system of the patient is more or less compromised, leaving the patient vulnerable to various diseases. The Role of the H- Y antigen in Graft Rejection and Graft- vs . -Host Disease. In both mice and humans, one of the most interesting of the mHag has been the male specific antigen, H-Y. H-Y was identified through the observation that within an inbred mouse strain, most of the male-to-female skin grafts were rejected, whereas transplants in other sex combinations nearly always succeeded (2) . A similar antigen exists in humans (3) , and further studies have established that sex mismatch is a significant risk factor associated with graft rejection or the development of Graft-versus-host disease in bone marrow transplant recipients (3-6) . H-Y mismatch can lead to rejection of HLA-matched male organ and tissue grafts by female recipients, as well as of female bone marrow grafts by male recipients.
The H-Y antigen is ubiquitously expressed in different human tissues (4,7), and H-Y specific immune responses occur during the transplantation of organs, blood transfusion, and pregnancy (reviewed in 8) . However, the origin and function of H-Y antigens has eluded researchers for 40 years.
As with other mHag, the recognition of H-Y by T lymphocytes is MHC-restricted (3,9) , and it has been shown that some H-Y antigens are peptides derived from cellular proteins that are presented on the cell surface in association with MHC class I molecules (10) .
Attempts to Identify the Gene Encoding the H- Y Antigen, or to Characterize the H- Y Antigen . Even though the H-Y antigen was first discovered in 1955, the gene encoding the H-Y antigen has not previously been identified, and this has hampered the development of certain immunological solutions to the health risks posed by H-Y antigen-mediated graft rejections.
The human H-Y gene has been mapped to the long arm of the Y chromosome (21) , while the mouse H-Y gene is believed to reside on "deletion interval 2" of the short arm of the murine Y chromosome (23) . The latter paper suggested that at least two and up to five distinct loci encode H-Y antigens.
Peptides have been extracted by acid elution from lysates of splenocytes of male and female mice and separated by reverse- phase HPLC. H-Y-specific CTLs (11P9 cell line) recognized fraction 28 from the male cell lysate, but not from the female lysate, suggesting that this fraction contained a CTL epitopic fragment of the H-Y antigen (10) . However, this fraction was not further resolved or characterized.
The SMCX and SMCY Genes . A mouse gene, smcy, was found in the course of a search of deletion interval 2 of the short arm of the Y chromosome (19) . The authors speculated as to the possibility that this gene encoded various antigens, including the H-Y antigen, the "serologically detected male antigen"
(SDMA) , and a spermatogenesis factor (Spy) . A related gene, smcx. which is found on the X chromosome, was also characterized. Agulnik, et al. , Id., 879-84. The genes are 78% identical at the nucleotide level. The translation products are 82% identical over a 321 amino acid stretch.
Identifica tion of T cell epi topes in Proteins . By combining microcapillary liquid chromatography/electrospray ionization mass spectrometry with T cell epitope reconstitution assays, we previously identified peptide antigens recognized by T cells specific for human melanoma (11; and see PCT/US95/01991,
USSN 08/234,784 and USSN 08/197,399) , human xenografts (12) , and a non-sex-linked human mHag (13) . However, the identification of a CTL epitope of an H-Y antigen has not previously been reported. Cytel, O94/03205 discloses methods for identifying HLA binding peptides.
No admission is made that any reference ci ted in this specification consti tutes prior art, or pertinent prior art . Applicants reserve the right to challenge the ci ted date of publication, or the accuracy of the data reported in any reference, if they are given reason to believe that these are incorrect or misleading.
SUMMARY OF THE INVENTION
Applicants have identified a peptide fragment recognized by a human cytotoxic T lymphocyte (CTL) clone that is H-Y specific and restricted by the class I MHC molecule HLA-B7. It is believed that this fragment represents a CTL epitope of the H-Y antigen. Such a fragment, and various derivatives, mutants, and conjugates of the fragment, are of value in predicting the likelihood of a severe graft-versus-host reaction to a transplant, as well as in preventing or ameliorating such a reaction.
Other embodiments and uses are set forth in this specification.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1. Reconstitution of the H-Y epitope with HPLC fractionated peptides extracted from HLA-B7 molecules. (A) HLA- B7 molecules were immunoaffinity purified from 2xl010 H-Y positive JY cells. Peptides were eluted from B7 molecules with 10% acetic acid, pH 2.2, filtered through a 10 kD cut-off filter and fractionated on a C18 reverse phase column. Buffer A was 0.1% heptafluorobutyric acid (HFBA) ; buffer B was 0.1% HFBA in acetonitrile. The gradient consisted of 100% buffer A (0-20 min) , 0 to 12% buffer B (20 to 25 min) , and 12 to 50% buffer B (25 to 80 min) at a flow rate of 200 μl/min. 60 fractions of 200 μl each were collected from 20 to 80 min. (B) Fractions 28
and 29 from the separation shown in (A) were rechromatographed with the same acetonitrile gradient, but using trifluoroacetic acid (TFA) instead of HFBA as the organic modifier. For both panels, 3% of each peptide fractions were preincubated with 1,000 51Cr-labeled T2-B7 cells at room temperature for 2 hours. CTLs were then added at an effector to target ratio of 10 to 1, and further incubated at 37°C for 4 hours. Background lysis of T2-B7 by the CTL in the absence of any peptides was -3% in (A) and -4% in (B) ; positive control lysis of JY was 75% in (A) and 74% in (B) .
Fig. 2. Determination of candidate H-Y peptide by mass spectrometry combined with 51Cr release assay. HPLC fraction 14 from the separation shown in Fig. IB was chromatographed with an on-line microcapillary column effluent splitter as previously described (11,13) One-fifth of the effluent was deposited into 100 μl of culture media in microtiter plate wells for analysis with CTLs as in Fig. 1. The remaining four-fifths of the material were directed into the electrospray ionization source, and mass spectra of the peptides deposited in each well were recorded on a triple-quadrupole mass spectrometer (Finnigan-MAT, San Jose, California) . (♦) , H-Y epitope reconstitution activity measured as percent specific lysis; (■) , abundance of peptide 1171 measured as ion current at m/z 391.
Fig. 3. CAD mass spectrum of peptide 1171 after conversion the R residue to ornithine. Material from second dimension HPLC fraction 14 shown in Fig. IB was treated with 70% hydrazine hydrate for 1 hour. The CAD mass spectrum was recorded on the (M+2H)+2ion at m/z 566.
Fig. 4. H-Y epitope reconstitution with synthetic peptides. Synthetic peptides were purified to homogeneity by reverse phase-HPLC on a Vydac C4 column. Purity was established on an analytical RP column and the quantity of each peptide was confirmed by comparing the area of the peak with that of a standard peptide. The identity of the peptides was confirmed by mass spectrometry. 51Cr release was assayed at an effector to target ratio of 10 to 1 on T2-B7 cells that had been incubated with the indicated concentration of SMCY peptide SPSVDKARAEL (•) , or SMCX peptide SPAVDKAQAEL (■) .
Fig. 5. Binding of synthetic peptides to purified HLA-B7. HPLC-purified test peptides were assayed for the ability to inhibit the binding of the iodinated endogenous B7 peptide APRTYVLLL to purified HLA-B7 as previously described (26) . ♦, SMCY peptide SPSVDKARAEL; ■, SMCX peptide SPAVDKAQAEL; A, APRTLVLLL, an endogenous peptide bound to HLA-B7; X, LLDVPTAAV, an endogenous peptide bound to HLA-A2.1 as the negative control.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION The present invention facilitates the inhibition of an adverse immune reaction to an H-Y antigen. Since the H-Y antigen is male specific, such a reaction is most often encountered when a female receives a donation of a male-derived organ or tissue transplant. However, if a transplant from a female donor to a male recipient includes immunocytes, as would be the case with a bone marrow transplant, then the transplanted T cells could react adversely to the H-Y+ cells native to the recipient. One of the purposes of the present invention, therefore, is to present an H-Y specific CTL epitope, as hereafter defined, to T cells in such a manner as to tolerize the T cells against a foreign H-Y antigen, thereby muting the immune response which would otherwise occur as a result of the transplantation.
Such tolerization may be achieved by any means known in the art. One such means is to repeatedly administer to the recipient very small doses of the immunogen. If desired, the size of the doses may be increased from time to time as the patient's ability to tolerate the immunogen increases. Another means is to administer the immunogen by a route of administration, such as the oral route, which is less effective, immunogenically, than the intravenous route. See einer, et al., Ann. Rev. Immunol., 12: 809-37 (1994) ; Friedman, et al. , Chem. Immunol. (Switz.) 58: 259-90 (1994) .
Another possibility is to administer an H-Y specific TCR antagonist . Certain antigen analogues have been found to be more efficient at inhibiting T cell activation by the parental antigen than are unrelated peptides. It has been speculated
that the TCR antagonist: MHC molecule complex competitively blocks the T-cell receptor so that it is nonresponsive to processed H-Y antigens, yet does not interact with the receptor in such a manner as to cause T cell activation. A partial agonist could also be useful. These can signal T cells for lymphocyte production but are unable to elicit the signals required for proliferation, presumably because of some abnormality in their interaction with the T-cell receptor.
For a review of TCR antagonists and partial agonists, see Sette, et al., Ann. Rev. Immunol., 12: 413-34 (1994) , and see also the references cited therein. Other relevant publications include Eckels, et al . , O90/08161 and Gefter, et al. , WO88/00057, and the references cited therein (including references cited in the attached International Search Reports) .
Yet another means of inducing tolerance is to block one or more of the pathways involved in the adverse immune response. For example, one may blockade the B7-CD28 or B7-CTLA4 pathway using anti-CD28 or anti-CTLA4 antibodies, and/or B7 analogues which act as antagonists by blocking the CD28 or CTLA4 binding site. See Boussiotis, et al. , Curr. Opin. Immunol. 6: 797-807 (1994) .
The H-Y specific epitope may be presented on an incomplete antigen-presenting cell, such as a T cell genetically engineered so as not to express CTLA4, or a fibroblast cell genetically engineered to express the necessary MHC molecule but not other molecules necessary for effective antigen presentation.
If desired, two or more means of tolerization may be used in combination, either simultaneously or sequentially, in order to achieve a greater degree of tolerance, or to achieve tolerance more rapidly, or to achieve it with fewer side effects. When such means are combined, it should be understood that the elements of the combination may be such that, if used alone, they would be ineffective.
An immune reaction to a foreign H-Y antigen may also complicate blood transfusions. The methods of the present invention may, mutatis mutandis, be adapted to the inhibition of serum sickness attributable to a transfusion between
individuals of different sexes .
Since H-Y reactions can occur in pregnancy (when a pregnant woman is bearing a male fetus) , the methods of the present invention may also be helpful in damping the immune response of the mother to the fetal H-Y antigen.
The compositions of the present invention also have diagnostic value. For example, they can be used to assess the degree of chimerization of the bone marrow of a patient who has received a sex-mismatched bone marrow transplant; the post- transplant marrow may include both H-Y+ and H-Y- T cells. Transplantation
The list of organs which may be transplanted is very long and is primarily limited by known surgical techniques. Certain tissues or parts of organs, as well as cells which are not organized into organs or tissues, also may be transplanted. For the purpose of the appended claims, the term "organ" includes whole organs, parts of organs, and miscellaneous tissues. Examples include kidney, eye, heart, heart valve, skin, liver, bone marrow, intestine, blood vessels, joints or parts thereof, pancreas or portions containing the islets, lungs, bronchi, brain tissue, muscle and any other vascularized tissue. However, the transfusion of blood or components thereof is not be construed as being an organ transplantation.
Transplantation may be performed to correct an organ which is missing, incomplete, or improperly functioning as a result of injury, genetic defect, disease, toxic reaction, etc. The recipient may receive the transplanted organ to supplement existing tissue such as using skin tissue to treat burns, pancreatic islets for diabetes or brain tissue for Parkinson's disease. Alternatively, the recipients defective organ may be completely removed and replaced with the graft such as in kidney, heart, liver, lung or joint transplants. For some organ transplants, either approach may be used, such as with liver transplants for treating cirrhosis and hepatic neoplasms and infections.
H-Y-Specific CTL Epitopes
The H-Y-specific CTL epitopes of the present invention are
peptides, typically 9-13 amino acids in length, which are sufficiently similar to an H-Y epitope recognized by an H-Y specific CTL to be useful, under suitable conditions of use, as tolerogens to protect an individual from an H-Y specific allogeneic response, or to be useful in the diagnosis of the susceptibility of an indiviual to such a response. Preferably, such epitopes are identical to or otherwise substantially homologous with H-Y-specific peptide epitopes recognized by H-Y- specific CTLs. Applicants believe that SMCY is likely to be either an H-Y antigen, or at least substantially homologous with an H-Y antigen. Consequently, these peptides may be identical to, or otherwise substantially homologous with, SMCY (which appears to be one of the human H-Y antigens) and especially to the identified SPSVDKARAEL epitope. Since, in turn, SMCX is substantially homologous with SMCY, they may also be identical or otherwise substantially homologous to SMCX ( especially to its SPAVDKAQAEL sequence) .
The family of H-Y epitopes which are recoverable from an individual is dependent on the nature of the binding site of the Class I MHC (HLA) molecules expressed by the individual, and, as a result of the polymorphism of the Class I MHC (HLA) molecules, can vary considerably from one individual to another. For the purpose of the present invention, the H-Y cell line used as a source of H-Y-specific CTL epitopes may be any H-Y cell line; similarly, the Class I MHC (HLA) molecule may be any such molecule which is capable of binding to and presenting a H-Y- specific epitope, including, but not limited to, the various allelic forms of Class I MHC molecules. Among the Class I molecules, the principal genetic loci are denoted as HLA-A, HLA- B, and HLA-C. The H-Y specific epitope of the present invention may be HLA-A, HLA-B or HLA-C restricted.
The preferred epitopic sequence may vary depending on the restriction system. Preferably, the H-Y specific epitope is one restricted by one of the more prevalent (at least among the intended patient population) allelic forms of these loci. Among HLA-A, the principle alleles are HLA-A2, -A3, -Al, -All and - A24. Among HLA-B, the most prevalent alleles are HLA-B7 and - B8; however, HLA-B is more polymorphic than HLA-A. Epitopes
presentable by HLA-B7 are of particular interest.
Preferably, the peptide concentration at which the epitope- stimulated CTLs achieve half the maximal increase in lysis relative to background is no more than about 1 nM, more preferably no more than about 100 pM, still more preferably no more than about 10 pM. For the peptide SPSVDKARAEL, the potency was 10 pm. Even when a peptide is being used as a tolerogen, high potency is advantageous as it permits use of low concentrations of the peptide, which, besides being more economical, also reduces the chance of a side effect.
Preferably the epitope is recognized by CTLs from at least two different individuals, more preferably at least five different individuals.
More preferably, the CTL epitope satisfies two or more of the above desiderata.
In a preferred embodiment, the H-Y epitope of the present invention has the sequence Ser-Pro-Ser-Val-Asp-Lys-Ala-Arg-Ala- Glu-Leu (SPSVDKARAEL) , or a functional fragment thereof.
Assuming that SMCY is identical to or otherwise substantially homologous with at least one H-Y antigen, other H-Y epitopes may be identified by systematic study of the immunological properties of 9-13 amino acid fragments of SMCY. Since, until the present discovery, the connection of SMCY to H-4 was highly speculative, and SMCY had no known biological function, the art lacked the motivation to make such a study. Alternatively, other H-Y epitopes may be identified as was SPSVDKARAEL, but by screening with other H-Y specific CTLs, especially those restricted by MHCs other than HLA-B7.
This peptide, although recognized by HLA-B7-restricted H-Y- specific CTL, may not be optimal at present. It is known that some residues on CTL epitopes are particularly important for binding of the peptide to the MHC molecule, while others are particularly important for Tc recognition. The other residues may be important for either or both. (refs: E.L. Huczko et al. J. Immunol. 151:2572, 1993; J. Ruppert et al . Cell 754: 929, 1993; Madden Dr et al . Cell 75:693-708, 1994.) It is proposed that amino acid substitutions for the peptide may be useful at altering the immune response to the peptide. Using existing
knowledge about which of these residues may be more likely to affect binding either to the MHC or to the TcR, a rational approach to this process may be employed. The resulting peptides, if more effective, could be used for any of the purposes described herein.
Therefore, in addition to epitopes which are identical to the naturally occurring H-Y-specific epitopes, the present invention embraces epitopes which are substantially homologous with such epitopes, and therefore H-Y-specific in their own right.
The term "substantially homologous", when used in connection with amino acid sequences, refers to sequences which are substantially identical to or similar in sequence with each other, giving rise to a homology in conformation and thus to retention, to a useful degree, of one or more biological (including immunological) activities. The term is not intended to imply a common evolution of the sequences.
Substantially homologous peptide epitopes may be identified by a variety of techniques. It is known in the art that one may synthesize all possible single substitution mutants of a known peptide epitope. Geysen, et al., Proc Nat. Acad. Sci. (USA) , 81:3998-4002 (1984) . For SPSVDKARAEL, there are only (19x11=) 209 such mutants. While the effects of different substitutions are not always additive, it is reasonable to expect that two favorable or neutral single substitutions at different residue positions in the epitope can safely be combined in most cases.
One may also synthesize a family of related single or multiple substitution mutants, present the mixture to a cell line (such as HLA-B7+, H-Y- T2-B7 cells) capable of presenting H-Y-specific CTL epitopes, and expose the cells to suitably restricted (e.g., HLA-B7) H-Y-specific CTLs. If the cells are lysed, the effective epitopes may be identified either by direct recovery from the T2 cells or by a progressive process of testing subsets of the effective peptide mixtures. Methods for the preparation of degenerate peptides are described in Rutter, USP 5,010,175, Haughten, et al . , Proc. Nat. Acad. Sci. (USA) , 82:5131-35 (1985) , Geysen, et al . , Proc. Nat. Acad. Sci. (USA) , 81:3998-4002 (1984) ; W086/06487; W086/00991.
In devising a multiple mutagenesis strategy, a person of ordinary skill would of course give weight to the single substitution mutant data in determining both which residues to vary and which amino acids (or classes of amino acids) are suitable replacements.
The person of ordinary skill in the art, in determining which residues to vary, may also make comparisons of the sequences of the naturally processed MHC associated peptides, and may obtain 3D structures of the MHC: peptide: TCR complexes, in order to identify residues involved in MHC or TCR binding. Such residues may either be left alone, or judiciously mutated in an attempt to alter MHC or TCR binding.
It is also possible to predict substantially homologous epitopes by taken into account studies of sequence variations in families of naturally occurring homologous proteins. (In view of certain observed sequence homologies discussed in the Examples, proteins of myosin class I may be especially relevant.) Certain amino acid substitutions are more often tolerated than others, and these are often correlatable with similar-ities in size, charge, etc. between the original amino acid and its replacement. Insertions or deletions of amino acids may also be made.
Conservative substitutions are herein defined as exchanges within one of the following five groups: I. Small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr, Pro, Gly
II. Polar, negatively charged residues: and their amides Asp, Asn, Glu, Gin
III. Polar, positively charged residues: His, Arg, Lys
IV. Large, aliphatic, nonpolar residues: Met, Leu, Ile, Val, Cys V. Large, aromatic residues: Phe, Tyr, Trp Within the foregoing groups, the following substitutions are considered "highly conservative" :
Asp/Glu His/Arg/Lys Phe/Tyr/Trp Met/Leu/Ile/Val Semi-conservative substitutions are defined to be exchanges between two of groups (I)-(V) above which are limited to supergroup (A) , comprising (I) , (II) and (III) above, or to supergroup (B) , comprising (IV) and (V) above.
As discussed hereafter, a double substitution mutant (Ser3- >Ala; Arg8->Gln) of the lead peptide was still able to sensitize
T2-B7 cells for recognition, but had only 1/10, 000th the potency of the lead peptide. However, since the purpose of the invention is not to achieve a strong immune response, but rather a muted one that serves to tolerize against the H-Y antigen, such a mutant may well be useful, indeed, it could be more useful than the native epitope. In this regard, it is desirable to note that while the Ser->Ala mutation is a relatively conservative one (one small, aliphatic, uncharged a.a. for another) , the Arg->Gln mutation is not. Further mutagenesis experiments are necessary to determine whether the change in potency is attributable to the loss of H-bonding potential (by replacing Ser with Ala) , the loss of the charge of the Arg, and/or a steric effect .
In the case of the aformentioned peptide, a possible multiple mutagenesis strategy could be the following: Parental Ser Pro Ser Val Asp Lys Ala Arg Ala Glu Leu
Replaced Ala Ala Ala Ile Glu Arg Ser Lys Ser Asp Ile by Thr Thr Thr Leu Asn His Thr His Thr Asn Val
Gly Gly Gly Met Gin Gly Gin Met Pro Ser Pro Pro wherein each amino acid sequence in the parental sequence may either be retained, or replaced by one of the amino acids in the column below it, selected independently.
Substitutions are not limited to the genetically encoded, or even the naturally occurring amino acids. When the epitope is prepared by peptide synthesis, the d- -ired amino acid may be used directly. Alternatively, a geneti .i-ly en- ed amino acid
may be modified by reacting it with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues. The following examples of chemical derivatives are provided by way of illustration and not by way of limitation.
Aromatic amino acids may be replaced with D- or L-naphylalanine, D- or L-Phenylglycine, D- or L-2-thieney- lalanine, D- or L-1-, 2-, 3- or 4-pyreneylalanine, D- or L-3-thieneylalanine, D- or L- (2-pyridinyl) -alanine, D- or L- (3-pyridinyl) -alanine, D- or L- (2-pyrazinyl) -alanine, D- or L- (4-isopropyl) -phenylglycine, D- (trifluoromethyi) - phenyl¬ glycine, D- (trifluoromethyi) -phenylalanine, D-p-fluoro- phenylalanine, D- or L-p-biphenylphenylalanine, D- or L-p-methoxybiphenylphenylalanine, D- or L-2-indole- (alkyl) alanines, and D- or L-alkylainines where alkyl may be substituted or unsubstituted methyl, ethyl, propyl, hexyl, butyl, pentyl, iso-propyl, iso-butyl, sec-isotyl, iso-pentyl, non-acidic amino acids, of C1-C20.
Acidic amino acids can be substituted with non-carboxylate amino acids while maintaining a negative charge, and derivatives or analogs thereof, such as the non-limiting examples of
(phosphono) -alanine, glycine, leucine, isoleucine, threonine, or serine; or sulfated (e.g., -S03H) threonine, serine, tyrosine. Other substitutions may include unnatural hyroxylated amino acids made by combining "alkyl" (as defined and exemplified herein) with any natural amino acid. Basic amino acids may be substituted with alkyl groups at any position of the naturally occurring amino acids lysine, arginine, ornithine, citrulline, or (guanidino) -acetic acid, or other (guanidino) alkyl-acetic acids, where "alkyl" is define as above. Nitrile derivatives (e.g., containing the CN-moiety in place of COOH) may also be substituted for asparagine or glutamine, and methionine sulfoxide may be substituted for methionine. Methods of preparation of such peptide derivatives are well known to one skilled in the art.
In addition, any amide linkage can be replaced by a
ketomethylene moiety, e.g. (-C (=0) -CH2-) for (- (C=0) -NH-) . Such derivatives are expected to have the property of increased stability to degradation by enzymes, and therefore possess advantages for the formulation of compounds which may have increased in vivo half lives, as administered by oral, intravenous, intramuscular, intraperitoneal, topical, rectal, intraocular, or other routes.
In addition, any amino acid can be replaced by the same amino acid but of the opposite chirality. Thus, any amino acid naturally occurring in the L-configuration (which may also be referred to as the R or S configuration, depending upon the structure of the chemical entity) may be replaced with an amino acid of the same chemical structural type, but of the opposite chirality, generally referred to as the D- amino acid but which can additionally be referred to as the R- or the S-, depending upon its composition and chemical configuration. Such derivatives have the property of greatly increased stability to degradation by enzymes, and therefore are advantageous in the formulation of compounds which may have longer in vivo half lives, when administered by oral, intravenous, intramuscular, intraperitoneal, topical, rectal, intraocular, or other routes.
Additional amino acid modifications of amino acids may include the following: Cysteinyl residues may be reacted with alpha-haloacetates (and corresponding amines) , such as 2-chloroacetic acid or chloroacetamide, to give carboxymethyl or carboxyamidomethy1 derivatives. Cysteinyl residues may also be derivatized by reaction with compounds such as bromotrifluoroacetone, alpha-bromo- beta- (5-imidozoyl)propionic acid, chloroacetyl phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide, methyl 2-pyridyl disulfide, p-chloromercuribenzoate, 2-chloromercuri-4-nitrophenol, or chloro-7-nitrobenzo-2-oxa-l, 3-diazole.
Histidyl residues may be derivatized by reaction with compounds such as diethylprocarbonate e.g., at pH 5.5-7.0 because this agent is relatively specific for the histidyl side chain, and para-bromophenacyl bromide may also be used; e.g., where the reaction is preferably performed in 0.1 M sodium cacodylate at pH 6.0.
Lysinyl and amino terminal residues may be reacted with compounds such as succinic or other carboxylic acid anhydrides. Derivatization with these agents is expected to have the effect of reversing the charge of the lysinyl residues. Other suitable reagents for derivatizing alpha-amino-containing residues include compounds such as imidoesters/e.g. , as methyl picolinimidate ; pyridoxal phosphate; pyridoxal; chloroborohydride ; trinitrobenzenesulfonic acid; O-methylisourea; 2,4 pentanedione; and transaminase-catalyzed reaction with glyoxylate.
Arginyl residues may be modified by reaction with one or several conventional reagents, among them phenylglyoxal, 2, 3-butanedione, 1, 2-cyclohexanedione, and ninhydrin according to known method steps. Derivatization of arginine residues requires that the reaction be performed in alkaline conditions because of the high pKa of the guanidine functional group. Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group.
The specific modification of tyrosyl residues per se is well-known, such as for introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane. N-acetylimidizol and tetranitromethane may be used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively. Carboxyl side groups (aspartyl or glutamyl) may be selec¬ tively modified by reaction with carbodiimides (R' -N-C-N-R' ) such as l-cyclohexyl-3- (2-morpholinyl- (4-ethyl) carbodiimide or 1- ethyl-3- (4-azonia-4,4- dimethylpentyl) carbodiimide. Furthermore, aspartyl and glutamyl residues may be converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.
Glutaminyl and asparaginyl residues may be readily deamidated to the corresponding glutamyl and aspartyl residues. Alternatively, these residues may be deamidated under mildly acidic conditions. Either form of these residues falls within the scope of the present invention.
Derivatization with bifunctional agents is useful for cross-linking the peptide to a water-insoluble support matrix
or to other macromolecular carriers, according to known method steps. Commonly used cross-linking agents include, e.g., 1, 1-bis (diazoacetyl ) -2 -phenylethane , glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'- dithiobis (suc- cinimidylpropionate) , and bifunctional maleimides such as bis-N-maleimido-1, 8-octane. Derivatizing agents such as methyl -3 - [ (p-azidophenyl ) dithio] propioimidate yield photoactivatable intermediates that are capable of forming crosslinks in the presence of light. Alternatively, reactive water-insoluble matrices such as cyanogen bromide-activated carbohydrates and the reactive substrates described in U.S. Patent Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and 4,330,440 (which are herein incorporated entirely by reference) , may be employed for protein immobilization.
Other modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the alpha-amino groups of lysine, arginine, and histidine side chains (Creighton, T.E., Proteins: Structure and Molecule Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)) , acetylation of the N-terminal amine, methylation of main chain amide residues (or substitution with N-methyl amino acids) and, in some instances, amidation of the C-terminal carboxyl groups, according to known method steps. Glycosylation is also possible.
Derivatized moieties may improve the solubility, absorption, biological half life, and the like, or eliminate or attenuate any possible undesirable side effect of the molecule. Moieties capable of mediating such effects are disclosed, for example, in Remington's Pharmaceutical Sciences. 16th ed. , Mack Publishing Co., Easton, PA (1980) .
Modifications are not limited to the side chains of the amino acids. One may also modify the peptidyl linkage itself, e.g., -NRCO- (where R is alkyl or aryl), instead of -NHC0-, as in the so-called "peptoids".
It is also possible to construct and use so-called peptide mimetics whose conformation is similar to that of a peptide but
do not have a peptide-like molecular formula.
The H-Y-Specific Tolerogen
The H-Y-specific tolerogen of the present invention is a molecule corresponding to or otherwise comprising a H-Y-specific CTL epitope as previously described. The tolerogen may comprise one or more H-Y-specific CTL epitopes, which may be the same or different. If different, the epitopes may be chosen so that at least one epitope is effective in each of two or more restriction systems, e.g., HLA-B7 and HLA-A2. If the tolerogen comprises a plurality of such epitopes, they may be linked directly, or through a spacer of some kind, or by noncovalent means such as an avidin:biotin complex. The tolerogen may take any form that is capable of eliciting a H-Y-specific tolerizing immune response. The tolerogenic conjugate may also comprise moieties intended to diminish the immune response, such as certain cytokines.
A variety of non- (H-Y) specific tolerogens are known which may either be conjugated to the H-Y specific epitope to form a unitary tolerogen, and/or used as independent molecules (either in the same composition or in a separately administered composition administered as part of the medication schedule) .
Mode of Production
The peptide portion of the tolerogens of the present invention may be produced by any conventional technique, including
(a) nonbiological synthesis by sequential coupling of component amino acids,
(b) production by recombinant DNA techniques in a suitable host cell, and (c) chemical or enzymatic modification of a sequence made by (a) or (b) above. In view of the size of the epitopes, and the practicality of using the epitopic peptides directly as tolerogens, method (a) is preferred. However, if it becomes advantageous to produce peptides longer than about 50 amino acids, method (b) is preferred.
Gene Expression . The peptides disclosed herein may be produced, recombinantly, in a suitable host, such as bacteria from the genera Bacillus, Escherichia, Salmonella, Erwinia, and yeasts from the genera Hansenula, Kluyveromyces, Pichia, Rhinosporidium, Saccharomyces, and Schizosaccharomyces, insect cells, or cultured mammalian cells such as COS-l, CHO and C127. The more preferred hosts are microorganisms of the species Pichia pastoris, Bacillus subtilis , Bacillus brevis, Saccharomyces cerevisiae, Escherichia coli and Yarrowia lipolytica . Any promoter, regulatable or constitutive, which is functional in the host may be used to control gene expression.
Standard reference works setting forth the general principles of recombinant DNA technology include Watson, J.D., et al. , Molecular Biology of the Gene, Volumes I and II, The
Benjamin/Cummings Publishing Company, Inc., publisher, Menlo
Park, CA (1987) ; Darnell, J.E., et al . , Molecular Cell Biology.
Scientific American Books, Inc., publisher, New York, N.Y.
(1986) ; Lewin, B.M., Genes II, John Wiley & Sons, publishers, New York, N.Y. (1985) ; Old, R.W. , et al. , Principles of Gene Manipulation: An Introduction to Genetic Engineering, 2d edition, University of California Press, publisher, Berkeley, CA (1981) ; Sambrook, J. , et al . , Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1989) ; and Ausubel, et al . , Current Protocols in
Molecular Biology, Wiley Interscience, N.Y. , (1987, 1992) .
These references are herein entirely incorporated by reference.
Chemical Peptide Synthesis . Chemical peptide synthesis is a rapidly evolving area in the art, and methods of solid phase peptide synthesis are well-described in the following references, hereby entirely incorporated by reference:
(Merrifield, B., J. Amer. Chem. Soc. 8j5:2149-2154 (1963) ;
Merrifield, B., Science 232 :341-347 (1986) ; Wade, J.D. , et al. ,
Biopolymers 25_:S21-S37 (1986) ; Fields, G.B., Int. J. Polypeptide Prot. Res. 35:161 (1990) ; MilliGen Report Nos. 2 and 2a, Millipore Corporation, Bedford, MA, 1987) Ausubel, et al, supra, and Sambrook, et al, supra.
In general, as is known in the art, such methods involve blocking or protecting reactive functional groups, such as free amino, carboxyl and thio groups. After polypeptide bond formation, the protective groups are removed (or de-protect-ed) . Thus, the addition of each amino acid residue requires several reaction steps for protecting and deprotecting. Current methods utilize solid phase synthesis, wherein the C-terminal amino acid is covalently linked to an insoluble resin particle large enough to be separated from the fluid phase by filtration. Thus, reactants are removed by washing the resin particles with appropriate solvents using an automated programmed machine. The completed polypeptide chain is cleaved from the resin by a reaction which does not affect polypeptide bonds.
In the more classical method, known as the "tBoc method, " the amino group of the amino acid being added to the resin-bound C-terminal amino acid is blocked with tert-butyloxycarbonyl chloride (tBoc) . This protected amino acid is reacted with the bound amino acid in the presence of the condensing agent dicyclohexylcarbodiimide, allowing its carboxyl group to form a polypeptide bond the free amino group of the bound amino acid. The amino-blocking group is then removed by acidification with trifluoroacetic acid (TFA) ; it subsequently decomposes into gaseous carbon dioxide and isobutylene. These steps are repeated cyclically for each additional amino acid residue. A more vigorous treatment with hydrogen fluoride (HF) or trifluoro-methanesulfonyl derivatives is common at the end of the synthesis to cleave the benzyl-derived side chain protecting groups and the polypeptide-resin bond.
More recently, the preferred "Fmoc" technique has been introduced as an alternative synthetic approach, offering milder reaction conditions, simpler activation procedures and compatibility with continuous flow techniques. This method was used, e.g., to prepare the peptide sequences disclosed in the present application. Here, the x-amino group is protected by the base labile 9-fluorenylmethoxycarbonyl (Fmoc) group. The benzyl side chain protecting groups are replaced by the more acid labile t-butyl derivatives. Repetitive acid treatments are replaced by deprotection with mild base solutions, e.g., 20%
piperidine in dimethyl-formamide (DMF) , and the final HF cleavage treatment is eliminated. A TFA solution is used instead to cleave side chain protecting groups and the peptide resin linkage simultaneously. At least three different peptide-resin linkage agents can be used: substituted benzyl alcohol derivatives that can be cleaved with 95% TFA to produce a peptide acid, methanolic ammonia to produce a peptide amide, or 1% TFA to produce a protected peptide which can then be used in fragment condensation procedures, as described by Atherton, E., et al. , J. Chem. Soc. Perkin Trans. 1:538-546 (1981) and Sheppard, R.C., et al., Int. J. Polypeptide Prot. Res. 2JD:451-454 (1982) . Furthermore, highly reactive Fmoc amino acids are available as pentafluorophenyl esters or dihydro-oxobenzotriazine esters derivatives, saving the step of activation used in the tBoc method.
Pharmaceutical Use
The pharmaceutical compositions of the present invention may be used to protect mammals against allogeneic immune responses to a foreign H-Y antigen. One or more such compositions will be used as part of a tolerogenically effective medication schedule to achieve such protection.
By the term "mammal" is meant an individual belonging to the class Mammalia, which, of course, includes humans. The invention is particularly useful in the treatment of human subjects, although it is intended for veterinary uses as well. Among mammals, the subject preferably belonds to the order
Primata (humans, apes, and monkeys) , Artiodactyla (e.g., cows, pigs, sheeps, goats, horses) , Rodenta (e.g., rabbits, mice, rats) , or Carnivora (e.g., cats, dogs) . Primates are especially preferred.
By the term "non-human primate" is intended any member of the suborder Anthropoidea except for the family Hominidae. Such non-human primates include the superfamily Ceboidea, family Cebidae (the New World monkeys including the capuchins, howlers, spider monkeys and squirrel monkeys) and family Callithricidae
(including the marmosets) ; the superfamily Cercopithecoidea,
family Cercopithecidae (including the macaques, mandrills, baboons, proboscis monkeys, mona monkeys, and the sacred hunaman monkeys of India) ; and superfamily Hominoidae, family Pongidae (including gibbons, orangutans, gorillas, and chimpanzees) . The rhesus monkey is one member of the macaques.
The term "protection", as used herein, is intended to include "prevention," "suppression" and "treatment." "Prevention" involves administration of the protective composition prior to the induction of the disease. "Suppression" involves administration of the composition prior to the clinical appearance of the disease. "Treatment" involves administration of the protective composition after the appearance of the disease.
It will be understood that in human and veterinary medicine, it is not always possible to distinguish between "preventing" and "suppressing" since the ultimate inductive event or events may be unknown, latent, or the patient is not ascertained until well after the occurrence of the event or events. Therefore, it is common to use the term "prophylaxis" as distinct from "treatment" to encompass both "preventing" and "suppressing" as defined herein. The term "protection, " as used herein, is meant to include "prophylaxis."
It should also be understood that to be useful, the protection provided need not be absolute, provided that it is sufficient to carry clinical value. An agent which provides protection to a lesser degree than do competitive agents may still be of value if the other agents are ineffective for a particular individual, if it can be used in combination with other agents to enhance the overall level of protection, or if it is safer than competitive agents.
The form of administration may be systemic or topical. For example, administration of such a composition may be by various parenteral routes such as subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intranasal, transdermal, or buccal routes. Alternatively, or concurrently, administration may be by the oral route. Parenteral administration can be by bolus injection or by gradual perfusion over time.
A typical regimen (medication schedule) comprises administration of an effective amount of the tolerogen, administered over a period ranging from a single dose, to dosing over a period of hours, days, weeks, months, or years. The doses may be equal in size, or different. If different, they may increase, or decrease, in a regular manner, or otherwise. The physician will usually exercise medical discretion and decrease or increase the dose after consideration of the effect of the initial dose(s) on the patient. Similarly, the interval between doses may be constant, or it may be increased or decreased.
It is understood that the suitable dosage of a tolerogen of the present invention will be dependent upon the age, sex, health, and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. However, the most preferred dosage can be tailored to the individual subject, as is understood and determinable by one of skill in the art, without undue experimentation. This will typically involve adjustment of a standard dose, e.g., reduction of the dose if the patient has a low body weight .
Prior to use in humans, a drug will first be evaluated for safety and efficacy in laboratory animals. In human clinical studies, one would begin with a dose expected to be safe in humans, based on the preclinical data for the drug in question, and on customary doses for analogous drugs (if any) . If this dose is effective, the dosage may be decreased, to determine the minimum effective dose, if desired. If this dose is ineffective, it will be cautiously increased, with the patients monitored for signs of side effects. See, e.g., Berkow, et al . , eds., The Merck Manual, 15th edition, Merck and Co., Rahway, N.J., 1987; Goodman, et al. , eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edition, Pergamon Press, Inc., Elmsford, N.Y. , (1990) ; Avery' s Drug Treatment : Principles and Practice of Clinical Pharmacology and Therapeutics, 3rd edition, ADIS Press, LTD., Williams and Wilkins, Baltimore, MD. (1987) , Ebadi, Pharmacology. Little, Brown and Co., Boston, (1985) , which references and references
cited therein, are entirely incorporated herein by reference.
The total dose required for each treatment may be administered by multiple doses or in a single dose. The tolerogen may be administered alone or in conjunction with other therapeutics directed to the disease or directed to other symptoms thereof.
The appropriate dosage form will depend on the disease, the tolerogen, and the mode of administration; possibilities include tablets, capsules, lozenges, dental pastes, suppositories, inhalants, solutions, ointments and parenteral depots. See, e.g., Berker, supra, Goodman, supra, Avery, supra and Ebadi, supra. which are entirely incorporated herein by reference, including all references cited therein.
It is expected that each composition will include .001- 1,000 micrograms, more typically .1-1000 μg, of the peptide epitope, but applicants are not to be considered to be bound to this range. It is noted that in WO90/08162, the therapeutically effective concentration was expected to be on the order of 100 micromoles of the "replacing peptide". In addition to at least one tolerogen as described herein, a pharmaceutical composition may contain suitable pharmaceutically acceptable carriers, such as excipients, carriers and/or auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. See, e.g., Berker, supra, Goodman, supra, Avery, supra and Ebadi, supra, which are entirely incorporated herein by reference.
The composition of the present invention may also include any compound used in the prevention or treatment of graft rejection or graft-versus-host disease, such as an immunosuppressive agent, or a less specific tolerizing agent.
For discussion of immunosuppressive agents, tolerogens, tolerogenic conjugates, and/or tolerogenizing methods, see
Maiti, US 5,358,710; Conrad, US 5,276,013, Cohen, US 5,114,844; Burnierm US 5,061,786; Cianciolo, US 4,822,606; Lee, US 4,430,260; US 4,261,973; WO95/10301; WO94/07516; WO94/05323; W093/12145; W092/21981; WO91/10426; DD278,721; WO91/08773; EP 243,044; US 4,650,675; Scheper, et al . , Arch. Toxicol. Suupl .
16: 63-70 (1994) ; Abbas et al. , Semin. Immuno. , 5: 441-7 (1993) ; Adorini, Clin. Exp. Rheumatol., 11 Suppl . 8: S41-4 (1993) ; Lobo- Yeo, et al., Clin. Exp. Rheumatol., 11 Suppl. 8: S17-21 (1993) ; Olive et al . , Crit . Rev. Ther. Drug Carrier Syst, 10: 29-63 (1993) ; Rayner et al. , Immunol. Ser., 59: 359-76 (1993) ; Lo, Curr. Opin. Immunol., 4: 711-5 (1992) ; Dua et al . , Curr. Eye Res., 11 Suppl. 59-65 (1992) ; Sehon, Adv. Exp. Med. Biol., 303: 199-206 (1991) ; Sehon, Int. Arch. Allergy Appl. Immunol., 94: 11-20 (1991) ; Welsh, Pediatr. Nephrol . , 5: 622-9 (1991) ; Davies, et al., Transplant Proc, 23: 2248-9 (1991) ; Sehon, Adv. Exp.
Med. Biol., 251: 341-51 (1989) ; Borel, Concepts Immunopathol,
7: 145-61 (1989) ; ; Makay et al. , Postgrad. Med. J. , 64: 522-30
(1988) ; Miele, et al. , Endocr. Rev., 8: 474-90 (1987) ; Scott,
Crit. Rev. Immunol., 5: 1-25 (1984) ; Sehon, Ann. N.Y. Acad. Sci., 392: 55-70 (1982) ; Sehon, Prog. Allergy, 32: 161-202 (1982) ; Fidler, J. Exp. Med., 3: 491-506 (1979) ; Schneider, Pathol. Microbiol., 42: 254-66 (1975) .
H-Y Specific Diagnostic Agents
An H-Y specific diagnostic agent is (1) a molecule which is or which comprises an H-Y specific epitope as previously defined, and which is labeled, immobilized, or otherwise rendered suitable for diagnostic use, or (2) an antibody which specifically binds such an H-Y specific epitope, and which is labled, immobilized, or otherwise rendered suitable for diagnostic use.
Diagnostic Uses and Compositions
The diagnostic agents of the present invention may be used to screen a sample for the presence of an antigen with the same epitope, or with a different but cross-reactive epitope, or for the presence of CTLs which specifically recognize the corresponding epitopes. In particular, the assay may be used to determine (1) whether an intended recipient is likely to suffer, in the absence of treatment, a severe graft rejection or graft-vs . -host disease as a result of the immune response to a particular H-Y CTL epitope; and (2) whether, after transplantation of bone marrow from a female donor to a male
recipient, the post-transplant hematopoietic compartment of the bone marrow include a significant number of H-Y+ (i.e., native) cells.
The sample will normally be a biological fluid, such as blood, urine, lymphatic fluid, amniotic fluid, semen, saliva, tears, milk, or cerebrospinal fluid, or a fraction or derivative thereof, or a biological tissue, in the form of, e.g., a tissue section or homogenate. The preferred sample is blood, or a fraction or derivative thereof. Assays may be divided into two basic types, hetero-geneous and homogeneous. In heterogeneous assays, the interaction between the affinity molecule and the analyte does not affect the label, hence, to determine the amount or presence of analyte, bound label must be separated from free label. In homogeneous assays, the interaction does affect the activity of the label, and therefore analyte levels can be deduced without the need for a separation step.
Assays may also be divided into competitive and non- competitive formats. In the competitive format, the analyte competes with a labeled analyte analogue for binding to a binding partner. In a common noncompetitive format called a sandwich assay, the analyte is first bound by a capture reagent, and then by a tag reagent.
In order to detect the presence, or measure the amount, of an analyte, the assay must provide for a signal producing system
(SPS) in which there is a detectable difference in the signal produced, depending on whether the analyte is present or absent
(or, in a quantitative assay, on the amount of the analyte) .
The detectable signal may be one which is visually detectable, or one detectable only with instruments. Possible signals include production of colored or luminescent products, alteration of the characteristics (including amplitude or polarization) of absorption or emission of radiation by an assay component or product, and precipitation or agglutination of a component or product. The term "signal" is intended to include the discontinuance of an existing signal, or a change in the rate of change of an observable parameter, rather than a change in its absolute value. The signal may be monitored manually or
automatically.
The component of the signal producing system which is most intimately associated with the diagnostic reagent is called the
"label". A label may be, e.g., a radioisotope, a fluorophore, an enzyme, a co-enzyme, an enzyme substrate, an electron-dense compound, an agglutinable particle.
The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography. Isotopes which are particularly useful for the purpose of the present invention are 3H, 1251, 131I, 35S, 14C, and, preferably, 12SI .
It is also possible to label a compound with a fluorescent compound. When the fluorescently labeled anti-body is exposed to light of the proper wave length, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labelling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o- phthaldehyde and fluorescamine.
Alternatively, fluorescence-emitting metals such as 125Eu, or others of the lanthanide series, may be attached to the binding protein using such metal chelating groups as diethyl- enetriaminepentaacetic acid (DTPA) and ethylenediamine- tetraacetic acid (EDTA) .
The diagnostic agents also can be detectably labeled by coupling to a chemiluminescent compound. The presence of the chem-iluminescently labeled antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isolumino, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.
Likewise, a bioluminescent compound may be used to label the agents. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bio-luminescent compounds for purposes of labeling are luciferin, luciferase and
aequorin .
Enzyme labels, such as horseradish peroxidase, alkaline phosphatase, malate dehydrogenase, staphylococcal nuclease, δ-V- steroid isomerase, yeast alcohol dehydrogenase, α-glycero phosphate dehydrogenase, triose phosphate isomerase, asparaginase, glucose oxidase, -galactosidase, ribonuclease, glucose-6-phosphate dehydrogenase, glucoamylase and acetyl¬ choline esterase, are preferred. When an enzyme label is used, the signal producing system must also include a substrate for the enzyme. If the enzymatic reaction product is not itself detectable, the SPS will include one or more additional reactants so that a detectable product appears.
A label may be conjugated, directly or indirectly (e.g., through a labeled antibody) , covalently (e.g., with SPDP) or noncovalently, to the epitope, to produce a diagnostic reagent. Similarly, the epitope may be conjugated to a solid phase support to form a solid phase ("capture") diagnostic reagent. Suitable supports include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to its target. Thus the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc. Sex Selection
The peptides of the present invention may be used to generate cytotoxic lymphocytes (CTL) or monoclonal antibodies (mAb) that could be used to select for male and female sperm cells, allowing for the selection of the sex of a resulting embryo after fertilization. We and others have developed CTL that recognize peptides presented by human class I MHC molecules using mice that express the human class I molecules in transgenic form. This is accomplished by immunization of the
mice with the peptide, and removal and culture of T cells from the mice in the presence of additional peptide and interleukin 2. Stable long term T cell lines and clones can be obtained from the spleen cell culture and used as reagents. Similarly, these animals may be used to isolate antibodies directed against the complex of the peptide with an MHC molecule. Antibodies with this type of specificity have been previously reported in the literature. In the context of the present invention, we would produce CTL and mAb directed against the complex of (1) a class I MHC molecule and (2) an H-Y and/or SMCY-epitope bearing peptide.
Such CTL or mAb could be used in either of two methods for selecting sperm of the appropriate sex. In the negative selection method, CTL would be added to a population of sperm. The CTL would directly kill any sperm cells expressing the peptide-MHC complex for which the CTL was specific. For example, CTL directed against a male specific H-Y peptide and/or SMCY peptide would kill all male (Y-chromosome bearing) sperm, leaving the female (non-Y-chromosome bearing) sperm. A similar end could be achieved using a complement fixing mAb directed against the same antigen, after addition of complement. In the second method, positive selection, an antibody of the appropriate specificity would be coupled to a plastic dish or a magnetic bead, allowing the binding and separation of sperm bearing the appropriate antigen. In either method, the sperm selected would be used for fertilization of eggs, followed by reimplantation of the eggs into a suitable host.
EXAMPLES
Cytotoxicity Assays Cell-mediated killing was determined in vitro using a 4-h chromium release assay. 51Cr-labeled target cells were plated at 2 x 103 cells/well in triplicate on 96-well V-bottom plates (Costar, Cambridge, MA) with varying numbers of effector cells in a final volume of 250 microl . Wells containing either culture medium and target cells only or 1 M HCl and target cells served as background 51Cr release controls and total release controls, respectively. The plates were centrifuged at 100 x
g for 3 min and incubated at 37°C in 5% C02 for 4 h. The plates were again centrifuged, and 0.20 ml of medium from each well was removed for counting in a gamma counter. The cytotoxic index was calculated as: Cpm (experimental) - cpm (background)
Cpm (total release) - cpm (background) Lytic units were calculated for several of the cytotoxicity as¬ says, using a software package prepared by the National Cancer Institute (Bethesda, MD) , which solves for the equation y = A x [1 - exp(-kx)] , where x is the E:T ratio, y is the cytotoxic index, A is the curve maximum, and k is a constant used to calculate the slope of the best fit line. For the purposes of this study, a lytic unit was defined as the number of effector cells needed to mediate 30% lysis of target cells. The number of lytic units was calculated per 105 effector cells (LU30 per 10s cells) . Isolation of H-Y Peptides
To isolate endogenously processed H-Y peptides, HLA-B7 molecules were purified by affinity chromatography from the H-Y positive, B lymphoblastoid cell line, JY (14) . The associated peptides were extracted in acid and separated from high molecular weight material by ultrafiltration as previously described (15) , and subsequently fractionated by reverse-phase high-performance liquid chromatography (HPLC) (11) . Aliquots of each fraction were incubated with HLA-B7 positive, H-Y negative T2-B7 target cells in order to assay for the ability to reconstitute the epitope recognized by an HLA-B7-restricted, H-Y specific CTL clone, 5W4 (16) A single peak of reconstituting activity was observed (Fig. IA, fraction 28 and 29) , which was rechromatographed using a different organic modifier. Although a single active peak of reconstituting activity was also observed from this separation (Fig IB, fraction 14, 15 and 16) , it still contained more than 100 distinct peptide species, as assessed by electrospray ionization tandem mass spectrometry.
To identify the active H-Y peptide in this mixture, we applied each active fraction separately to a microcapillary HPLC
column and split the effluent following the separation (11) : Four-fifths of the effluent was directed into the mass spectrometer for analysis, while one-fifth was simultaneously directed into a 96-well microtiter plate for a subsequent epitope reconstitution assay. The amount of the H-Y sensitizing activity in each well was correlated to signals observed in the mass spectrum, and therefore to the abundance of different peptide species. By comparing the profile of H-Y activity and the ion abundance data (Fig. 2) , we were able to identify an (M+3H) +3 ion at a mass-to-charge ratio (m/z) of 391 (neutral molecular mass =1171) , whose abundance correlated with the amount of H-Y epitope reconstituting activity. Further confirmation of the importance of peptide 1171 was provided by the demonstration that a peptide with an identical mass and collision-activated dissociation (CAD) spectrum was also present in HLA-B7 associated peptides extracted from a second H-Y positive B lymphoblastoid line, DM, but absent from a spontaneous H-Y antigen loss variant of this cell, DM(-) (17) .
Assignment of a complete amino acid sequence to the 1171 peptide from the CAD mass spectrum recorded at the 20 fmol level proved difficult due to the absence of high mass fragment ions containing the amine terminus (b-type ions) . A series of single and / or doubly charged fragment ions containing the carboxyl terminus (y-type ions) identified the C-terminal residue as either L or I and the first six amino acids as SPSVDK. The difference in molecular mass between this partial sequence and that of the full length peptide suggested the presence of four additional residues, for a total length of 11. Since the candidate peptide existed exclusively in the gas phase as an (M+3H) +3 ion, and underwent mass shifts of 42 and 84 Da on conversion to the corresponding methyl ester and acetylated derivative, respectively, two of the remaining residues were assigned as R and either D or E. Only two combinations of four residues (AREA and GRDV) meet the above criteria and satisfy the missing mass of 427 Da. CAD spectra recorded on synthetic peptides suggested that R could not be located at either position 7 or 10. Data bases were searched for proteins
containing peptides with these characteristics, and a sequence consistent at 9 out of 11 positions was found in residues 909- 919 of the protein encoded by a gene called XE169 or SMCX (18) , which is located on the X chromosome. A homolog of SMCX, called SMCY, is located on the Y chromosome (19) . This protein (20) contains a sequence (residues 902-912) that is consistent at 11 out of 11 positions, and has the expected mass of 1171 Da. A CAD mass spectrum recorded on the naturally processed material after conversion of the R residue to ornithine confirmed that its sequence was identical to that found in the SMCY protein (Fig. 3) . Sensitization and Affinity Assays
A synthetic peptide corresponding to the 11 residue SMCY sequence (SPSVDKARAEL) was found to sensitize T2-B7 cells for recognition by the H-Y specific CTL clone. Half-maximal lysis was achieved at a peptide concentration of 10 pM (Fig. 4) . The corresponding peptide derived from the sequence of the X chromosomal homolog, SMCX, has substitutions of A for S at position 3 and Q for R at position 8. Although this peptide also was able to sensitize T2-B7 cells for recognition, comparable levels of killing were only achieved by using a 10, 000-fold higher peptide concentration. Binding studies showed that the concentration of the SMCY peptide that inhibited the binding of an iodinated standard peptide to purified HLA-B7 by 50% (IC50) was 34 nM, while the IC50 for the SMCX peptide was 140 nM (Fig. 5) . Thus, the significant difference in the ability of the SMCY and SMCX peptides to sensitize targets for T cell recognition is almost entirely due to the fine specificity of the T cell receptor, rather than to differences in MHC binding affinities. The SMCX peptide is also present in naturally processed peptide extracts of HLA-B7, although its abundance is only 25% of that of the SMCY peptide (17) . Based on all of this information, we conclude that the peptide epitope representing the HLA-B7 restricted H-Y antigen is derived from the protein encoded by SMCY. However, it is possible that the H-Y antigen is a not previously identified homologoue of SMCY which happens to have the aforementioned peptide sequence in common with SMCY.
One interesting issue is whether the H-Y epitope peptides presented by other MHC molecules will also be derived from SMCY. SMCY and SMCX are 85% identical at the amino acid sequence level, and the SMCX gene is expressed ubiquitously from both the active and the inactive X chromosomes in both mice and human (18,22) . Therefore, self-tolerance to SMCX will limit the number of SMCY peptides that could give rise to H-Y epitopes in association with different MHC molecules. On the other hand, SMCY contains almost 1500 residues, and the over 200 amino acid sequence differences between it and SMCX are scattered relatively uniformly throughout its length. Thus, there is the potential to generate a large number of distinct SMCY-specific peptides as H-Y epitopes. It is still an open question whether the H-Y epitope peptides presented by other MHC molecules are also derived from SMCY. Genetic mapping of the mouse Y chromosome has suggested at least two and up to five distinct loci encoding H-Y antigens (23) . Interestingly, a murine H-Y epitope restricted by H-2Kk has also been shown to be derived from the murine Smcy protein (24) . The demonstration that two H-Y epitopes from either mouse or human are derived from the same protein makes SMCY the prime target in searching other H-Y epitopes.
The identification of the protein that gives rise to an H-Y antigen culminates 40 years of uncertainty regarding its origin. However, the function of SMCY, as well as the homologous SMCX, remains unclear. Both proteins share significant sequence homology to retinoblastoma binding protein 2, which has been suggested to be a transcription factor (25) . Nonetheless, this and other H-Y specific peptides are candidates for immunomodulatory approaches in bone marrow transplantation. They may also form the basis for genetic probes to be used for prenatal diagnosis in sex-linked congenital abnormalities, as well as for investigating minimal residual disease and chimerism. All references ci ted anywhere in this specifications , whether patents , patent applications , or nonpatent publications , are hereby incorporated by reference .
References
1. B. Loveland, E. Simpson, Immunol . Today 7, 223 (1986) .
2. E. J. Eichwald, C. R. Silmser, Transplant . Bull . 2, 148
(1955); R. E. Billingham, W. K. Silvers, J. Immunol . 85, 14 (1960) .
3. E. Goulmy, A. Termijtelen, B. A. Bradley, J. J. van Rood, Lancet 2, 1206 (1976) ; E. Goulmy, A. Termijtelen, B. A. Bradley, J. J. van Rood, Nature 266, 544 (1977) .
4. P. J. Voogt et al, Lancet 335, 131 (1990) . 5. Bone Marrow Transplantation 4, 221 (1989) .
6. M. M. Bortin, Transplant . Proc . 19, 2655 (1987) .
7. M. de Bueger, A. Bakker, J. J. van Rood, F. Van der Woude, E. Goulmy, J. Immunol . 149, 1788 (1992) ; D. van der Harst et al, Blood 83, 1060 (1994) . 8. E. Goulmy, in Transplantation Reviews, Vol . 2, P. J.
Morris and N. C. Tilney, Eds. (Saunders, Philadelphia,
1988) , p. 29. 9. R. D. Gordon, E. Simpson, L. E. Samelson, J". Exp . Med.
142, 1108 (1975) . 10. 0. Rotzschke, K. Falk, H. J. Wallny, S. Faath, H. G. fRammensee, Science 249, 283 (1990) .
11. A. L. Cox et al, Science 264, 716 (1994) .
12. R. A. Henderson et al, Proc . Natl . Acad. Sci . USA 90, 10275 (1993) . 13. J. M. M. den Haan et al, Science 268, 1476 (1995) .
14. M. J. Turner et al, J. Biol . Chem. 250, 4512 (1975) ; P. Parham, B. N. Alpert, H. T. Orr, J. L. Strominger, J. Biol . Chem . 252, 7555 (1977) .
15. D.F. Hunt et al, Science 255, 1261 (1992); E. L. Huczko et al, J. Immunol . 151, 2572 (1993) .
16. E. Goulmy, J. D. Hamilton, B. A. Bradley, J. Exp . Med. 149, 545 (1979) .
17. L. R. Meadows, W. Wang, N. E. Sherman, J. M. den Haan, unpublished results. 18. J. Wu et al, Human Molecular Genetics 3, 153 (1994) ; A. I. Agulnik et al, Human Molecular Genetics 3, 879 (1994) . 19. A. I. Agulnik, M. J. Mitchell, J. L. Lerner, D. R. Woods, C. E. Bishop, Human Molecular Genetics 3, 873 (1994) .
20. A. I. Agulnik, C. E. Bishop, unpublished results.
21. M. A. Cantrell, J. S. Bogan, E. Simpson, J. N. Bicknell, E. Goulmy, et al, Genomics 13, 1255 (1992) .
22. J. Wu et al, Nature Genetics 7, 491 (1994) . 23. T. R. King et al, Genomics 24, 159 (1994)
24. D. M. Scott et al, unpublished results.
25. A. R. Fattaey et al, Oncogene 8, 3149 (1993) .
26. J. Ruppert et al, Cell 74, 929 (1993) ; Y. Chen et al, J. Immunol . 152, 2874 (1994) ; A. Sette et al, J. Immunol . 153, 5586 (1994) .
Claims
1. A method of protecting a mammal against an undesired allogeneic immune response to an H-Y antigen which comprises administering to said mammal, according to a tolerogenically effective medication schedule, one or more doses of an H-Y specific tolerogen.
2. The method of claim 1 in which the mammal is a human.
3. The method of claim 1 wherein the mammal is H-Y- and is protected from an immune response to an H-Y+ transplanted organ.
4. The method of claim 1 wherein the mammal is H-Y+ and is protected from an immune response mediated by H-Y- immunocytes in an organ transplanted from an H-Y- individual.
5. The method of claim 1 wherein the immune response is attibutable to the transfusion of blood or blood components.
6. The method of claim 1 wherein the immune response is attributable to maternal recognition of fetal H-Y antigen.
7. The method of claim 1 wherein said tolerogen comprises an H-Y specific epitope which is identical to, or otherwise at least substantially homologous with, SPSVDKARAEL.
8. The method of claim 1 wherein said tolerogen comprises an H-Y specific epitope which is identical to, or otherwise at least substantially homologous with, SPAVDKAQAEL.
9. The method of claim 1 wherein said tolerogen comrpises an HLA-B restricted epitope.
10. The method of claim 9 wherein said epitope is HLA-B7 restricted.
11. The method of claim 10 wherein said epitope is recognized by the cell line 5W4.
12. A non-naturally occurring H-Y specific tolerogen.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU66028/96A AU6602896A (en) | 1995-07-28 | 1996-07-26 | H-y derived epitopes and uses therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US165295P | 1995-07-28 | 1995-07-28 | |
US60/001,652 | 1995-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997004798A1 true WO1997004798A1 (en) | 1997-02-13 |
Family
ID=21697154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/012351 WO1997004798A1 (en) | 1995-07-28 | 1996-07-26 | H-y derived epitopes and uses therefor |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6602896A (en) |
WO (1) | WO1997004798A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000077046A1 (en) * | 1999-06-11 | 2000-12-21 | Rijksuniversiteit Leiden | A male-specific protein homologue involved in histocompatability |
US7205119B2 (en) | 1997-07-23 | 2007-04-17 | Rijksuniversiteit Te Leiden | HA-1 antigen |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62138760A (en) * | 1985-12-12 | 1987-06-22 | Osaka Oxygen Ind Ltd | Immune globulin and its production and application |
-
1996
- 1996-07-26 WO PCT/US1996/012351 patent/WO1997004798A1/en active Application Filing
- 1996-07-26 AU AU66028/96A patent/AU6602896A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62138760A (en) * | 1985-12-12 | 1987-06-22 | Osaka Oxygen Ind Ltd | Immune globulin and its production and application |
Non-Patent Citations (8)
Title |
---|
AGULNIK ET AL: "A NOVEL X GENE WITH A WIDELY TRANSCRIBED Y-LINKED HOMOLOGUE ESCAPES X-INACTIVATION IN MOUSE AND HUMAN", HUMAN MOLECULAR GENETICS, vol. 3, no. 6, 1994, pages 879 - 884, XP002020886 * |
DEN HAAN ET AL: "IDENTIFICATION OF A GRAFT VERSUS HOST DISEASE-ASSOCIATED HUMAN MINOR HISTOCOMPATIBILITY ANTIGEN", SCIENCE, vol. 268, 9 June 1995 (1995-06-09), pages 1476 - 1480, XP002020887 * |
KING ET AL: "DELETION MAPPING BY IMMUNOSELECTION AGAINST THE H-Y HISTOCOMPATIBILITY ANTIGEN FURTHER RESOLVES THE SXRA REGION OF THE MOUSE Y CHROMOSOME AND REVEALS COMPLEXITY OF THE HYA LOCUS", GENOMICS, vol. 24, 1994, pages 159 - 168, XP000608200 * |
PATENT ABSTRACTS OF JAPAN vol. 11, no. 366 (P - 641) 28 November 1987 (1987-11-28) * |
PENNISI: "LONG-SOUGHT H-Y ANTIGEN FOUND", SCIENCE, vol. 269, 15 September 1995 (1995-09-15), pages 1515 - 1516, XP002020891 * |
RÖTZSCHKE ET AL: "CHARACTERIZATION OF NATURALLY OCCURRING MINOR HISTOCOMPATIBILITY PEPTIDES INCLUDING H-4 AND H-Y", SCIENCE, vol. 249, 1990, pages 283 - 287, XP002020888 * |
SCOTT ET AL: "IDENTIFICATION OF A MOUSE MALE-SPECIFIC TRANSPLANTATION ANTIGEN,H-Y", NATURE, vol. 376, 24 August 1995 (1995-08-24), pages 695 - 698, XP002020890 * |
WANG ET AL: "HUMAN H-Y: A MALE-SPECIFIC HISTOCOMPATIBILITY ANTIGEN DERIVED FROM THE SMCY PROTEIN", SCIENCE, vol. 269, 15 September 1995 (1995-09-15), pages 1588 - 1590, XP002020889 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7205119B2 (en) | 1997-07-23 | 2007-04-17 | Rijksuniversiteit Te Leiden | HA-1 antigen |
WO2000077046A1 (en) * | 1999-06-11 | 2000-12-21 | Rijksuniversiteit Leiden | A male-specific protein homologue involved in histocompatability |
EP1067141A1 (en) * | 1999-06-11 | 2001-01-10 | Rijksuniversiteit te Leiden | A male-specific protein homologue involved in histocompatibility |
Also Published As
Publication number | Publication date |
---|---|
AU6602896A (en) | 1997-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170267740A1 (en) | Peptides associated with hla-dr mhc class ii molecule and involved in rheumatoid arthritis | |
Wang et al. | Human HY: a male-specific histocompatibility antigen derived from the SMCY protein | |
JP3096739B2 (en) | Isolated nonapeptides presented by HLA molecules and uses thereof | |
US6509033B1 (en) | Immunomodulatory peptides | |
US6696061B1 (en) | Immunomodulatory peptides | |
EP0631502B1 (en) | Lymphocyte activity regulation by hla peptides | |
WO1994004171A9 (en) | Immunomodulatory peptides | |
JP2003520606A (en) | Novel MHC class II restricted T cell epitope derived from cancer antigen NYESO-1 | |
KR20010041238A (en) | Methods for treatment of diabetes using peptide analogues of insulin | |
US6660276B1 (en) | Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor | |
SA519410007B1 (en) | Peptides and methods for the treatment of diabetes | |
US7811993B2 (en) | Methods and compositions for treating melanoma | |
EP0753005B1 (en) | Cytotoxic t-cell lymphocyte ("ctl") activity regulation by class i mhc peptides | |
US6045796A (en) | Vaccination with peptide of MHC class II molecules for treatment of autoimmune disease | |
US7008922B2 (en) | H-Y antigen | |
AU2424397A (en) | Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor | |
WO1997004798A1 (en) | H-y derived epitopes and uses therefor | |
JP4065322B2 (en) | Synthetic peptides and pharmaceutical compositions containing them | |
US7019112B1 (en) | Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytoxic lymphocytes, and uses therefor | |
Tam et al. | T cell tolerance is influenced by concomitant T cell recognition of cross-reactive self-peptides. | |
JPH10337189A (en) | New compound | |
Brocke et al. | Inhibition of T cell proliferation specific for acetylcholine receptor epitopes related to myasthenia gravis with antibody to T cell receptor or with competitive synthetic polymers | |
CA2421321A1 (en) | Peptides associated with hla-dr mhc class ii molecule and involved in rheumatoid arthritis | |
KR20000070542A (en) | Peptides Comprising a T-Cell Epitope Specific to Collagen II | |
US20080280326A1 (en) | Novel Gonadotropin-Releasing Hormone, Precursor Peptides Thereof and Genes Encoding the Same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI JP MX NO NZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |